

CPC COOPERATIVE PATENT CLASSIFICATION

C CHEMISTRY; METALLURGY

(NOTES omitted)

CHEMISTRY

C12 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

(NOTES omitted)

C12N MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ([microbiological testing media C12Q 1/00](#))

NOTES

1. Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes.
2. Attention is drawn to Notes (1) to (3) following the title of Class [C12](#).
3. When classifying in this group, classification is also made in group [B01D 15/08](#) insofar as subject matter of general interest relating to chromatography is concerned.

WARNINGS

1. The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:

C12N 1/11	covered by	C12N 15/79
C12N 1/13	covered by	C12N 15/79
C12N 1/15	covered by	C12N 15/80
C12N 1/19	covered by	C12N 15/81
C12N 1/21	covered by	C12N 15/74
C12N 5/02	covered by	C12N 5/0006 , C12N 5/04 - C12N 5/166
C12N 5/07 - C12N 5/095	covered by	C12N 5/06
C12N 5/18	covered by	C12N 5/16
C12N 5/20	covered by	C12N 5/163
C12N 5/22	covered by	C12N 5/16
C12N 5/24	covered by	C12N 5/163
C12N 5/26	covered by	C12N 5/166
C12N 5/28	covered by	C12N 5/166
C12N 15/53	covered by	C12N 9/0004
C12N 7/01	covered by	C12N 7/00
C12N 9/02 - C12N 9/08	covered by	C12N 9/0004
C12N 9/26	covered by	C12N 9/2408
C12N 9/28 - C12N 9/30	covered by	C12N 9/2414 - C12N 9/242
C12N 9/32	covered by	C12N 9/2422
C12N 9/34	covered by	C12N 9/2428
C12N 9/36	covered by	C12N 9/2462
C12N 9/38	covered by	C12N 9/2468
C12N 9/40	covered by	C12N 9/2465
C12N 9/42	covered by	C12N 9/2434
C12N 9/44	covered by	C12N 9/2451
C12N 9/46	covered by	C12N 9/2454
C12N 9/56	covered by	C12N 9/54
C12N 9/66	covered by	C12N 9/6448
C12N 9/68	covered by	C12N 9/6435
C12N 9/70	covered by	C07K 14/3153
C12N 9/72	covered by	C12N 9/6462
C12N 9/74	covered by	C12N 9/6429
C12N 9/76	covered by	C12N 9/6427
C12N 15/05	covered by	C12N 5/14
C12N 15/06	covered by	C12N 5/16
C12N 15/07	covered by	C12N 5/16
C12N 15/08	covered by	C12N 5/166
C12N 15/12	covered by	C07K 14/435

C12N

C12N

(continued)

C12N 15/13	covered by	C07K 16/00
C12N 15/14	covered by	C07K 14/765
C12N 15/15	covered by	C07K 14/81
C12N 15/16	covered by	C07K 14/575
C12N 15/17	covered by	C07K 14/62
C12N 15/18	covered by	C07K 14/61
C12N 15/19	covered by	C07K 14/52
C12N 15/20	covered by	C07K 14/555
C12N 15/21	covered by	C07K 14/56
C12N 15/22	covered by	C07K 14/565
C12N 15/23	covered by	C07K 14/57
C12N 15/24	covered by	C07K 14/54
C12N 15/25	covered by	C07K 14/545
C12N 15/26	covered by	C07K 14/55
C12N 15/27	covered by	C07K 14/53
C12N 15/28	covered by	C07K 14/525
C12N 15/29	covered by	C07K 14/415
C12N 15/30	covered by	C07K 14/44
C12N 15/31	covered by	C07K 14/195 , C07K 14/005
C12N 15/32	covered by	C07K 14/325
C12N 15/33	covered by	C07K 14/005
C12N 15/34	covered by	C07K 14/01
C12N 15/35	covered by	C07K 14/015
C12N 15/36	covered by	C07K 14/02
C12N 15/37	covered by	C07K 14/025
C12N 15/38	covered by	C07K 14/03
C12N 15/39	covered by	C07K 14/065
C12N 15/40	covered by	C07K 14/08
C12N 15/41	covered by	C07K 14/085
C12N 15/42	covered by	C07K 14/09
C12N 15/43	covered by	C07K 14/105
C12N 15/44	covered by	C07K 14/11
C12N 15/45	covered by	C07K 14/115
C12N 15/46	covered by	C07K 14/14
C12N 15/47	covered by	C07K 14/145
C12N 15/48	covered by	C07K 14/15
C12N 15/49	covered by	C07K 14/155
C12N 15/50	covered by	C07K 14/165
C12N 15/51	covered by	C07K 14/02 , C07K 14/10 , C07K 14/18
C12N 15/53	covered by	C12N 9/0004
C12N 15/54	covered by	C12N 9/10
C12N 15/55	covered by	C12N 9/14
C12N 15/56	covered by	C12N 9/24
C12N 15/57	covered by	C12N 9/48
C12N 15/58	covered by	C12N 9/6456
C12N 15/59	covered by	C12N 9/6483
C12N 15/60	covered by	C12N 9/88
C12N 15/61	covered by	C12N 9/90
C12N 15/83	covered by	C12N 15/82
C12N 15/84	covered by	C12N 15/82

2. In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the scheme.

1/00	Microorganisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from protozoa, bacteria or viruses A61K 35/66 , from algae A61K 36/02 , from fungi A61K 36/06 ; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, A61K 39/00); Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor	1/02	• Separating microorganisms from their culture media
		1/04	• Preserving or maintaining viable microorganisms (immobilised microorganisms C12N 11/00)
1/005	• {after treatment of microbial biomass not covered by C12N 1/02 - C12N 1/08 }	1/06	• Lysis of microorganisms
		1/063	• • {of yeast}
		1/066	• • {by physical methods}
		1/08	• Reducing the nucleic acid content
		1/10	• Protozoa; Culture media therefor
		1/105	• • {Protozoal isolates}
		1/12	• Unicellular algae; Culture media therefor (as new plants A01H 13/00)
		1/125	• • {Unicellular algae isolates}

- 1/14 . Fungi (culture of mushrooms [A01G 18/00](#); as new plants [A01H 15/00](#)); Culture media therefor
- 1/145 . . {Fungal isolates}
- 1/16 . . Yeasts; Culture media therefor
- 1/165 . . . {Yeast isolates}
- 1/18 . . . Baker's yeast; Brewer's yeast
- 1/185 {Saccharomyces isolates}
- 1/20 . Bacteria; Culture media therefor
- 1/205 . . {Bacterial isolates}
- 1/22 . Processes using, or culture media containing, cellulose or hydrolysates thereof
- 1/24 . Processes using, or culture media containing, waste sulfite liquor
- 1/26 . Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using microorganisms [C10G 32/00](#))
- 1/28 . . aliphatic
- 1/30 . . . having five or less carbon atoms
- 1/32 . Processes using, or culture media containing, lower alkanols, i.e. C₁ to C₆
- 1/34 . Processes using foam culture
- 1/36 . Adaptation or attenuation of cells
- 1/38 . Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound ([C12N 1/34](#) takes precedence)

3/00 Spore forming or isolating processes

5/00 Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques [A01H 4/00](#))

NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage;
- "progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.

- 5/0006 . {Modification of the membrane of cells, e.g. cell decoration}
- 5/0012 . {Cell encapsulation}
- 5/0018 . {Culture media for cell or tissue culture (media for specific animal cell type [C12N 5/06](#))}
- 5/0025 . . {Culture media for plant cell or plant tissue culture}

- 5/0031 . . {Serum-free culture media}

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 5/0037](#) - [C12N 5/0056](#)

- 5/0037 . . {Serum-free medium, which may still contain naturally-sourced components}
- 5/0043 . . {Medium free of human- or animal-derived components}
- 5/005 . . {Protein-free medium}
- 5/0056 . . {Xeno-free medium}
- 5/0062 . {General methods for three-dimensional culture}
- 5/0068 . {General culture methods using substrates (for specific animal cell type [C12N 5/06](#))}
- 5/0075 . . {using microcarriers}
- 5/0081 . {Purging biological preparations of unwanted cells}
- 5/0087 . . {Purging against subsets of blood cells, e.g. purging alloreactive T cells}
- 5/0093 . . {Purging against cancer cells}
- 5/04 . Plant cells or tissues {(culture media [C12N 5/0025](#))}
- 5/06 . {Animal cells or tissues; Human cells or tissues (preservation of living cells or tissues [A01N 1/02](#))}

NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage.

"Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells

- 5/0601 . . {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}
- 5/0602 . . {Vertebrate cells}

NOTE

Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

- 5/0603 . . . {Embryonic cells (production of embryos, nuclear transfer [A01K 67/027](#)); Embryoid bodies}
- 5/0604 {Whole embryos; Culture medium therefor}
- 5/0605 {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}

5/0606 {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N 5/0611 , induced pluripotent stem cells C12N 5/0696)}	5/0642 {Granulocytes, e.g. basophils, eosinophils, neutrophils, mast cells}
5/0607 {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N 5/0696)}	5/0643 {Osteoclasts}
5/0608 {Germ cells (production of embryos, nuclear transfer A01K 67/027)}	5/0644 {Platelets; Megakaryocytes}
5/0609 {Oocytes, oögonia (fertilised oocytes C12N 5/0604)}	5/0645 {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
5/061 {Sperm cells, spermatogonia}	5/0646 {Natural killers cells [NK], NKT cells}
5/0611 {Primordial germ cells, e.g. embryonic germ cells [EG]}	5/0647 {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
5/0612 {sorting of gametes, e.g. according to sex or motility}	5/0648 {Splenocytes}
5/0613 {Cells from endocrine organs (pancreas C12N 5/0676 , gonads C12N 5/0681)}	5/065 {Thymocytes}
5/0614 {Adrenal gland}	5/0651 {Lymph nodes}
5/0615 {Pineal gland}	5/0652 {Cells of skeletal and connective tissues; Mesenchyme}
5/0616 {Pituitary gland}	5/0653 {Adipocytes; Adipose tissue}
5/0617 {Thyroid and parathyroid glands}	5/0654 {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}
5/0618 {Cells of the nervous system}	5/0655 {Chondrocytes; Cartilage}
5/0619 {Neurons}	5/0656 {Adult fibroblasts}
5/062 {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}	5/0657 {Cardiomyocytes; Heart cells}
5/0621 {Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N 5/062)}	5/0658 {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}
5/0622 {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}	5/0659 {Satellite cells}
5/0623 {Stem cells}	5/066 {Tenocytes; Tendons, Ligaments}
5/0625 {Epidermal cells, skin cells; Cells of the oral mucosa}	5/0661 {Smooth muscle cells}
5/0626 {Melanocytes}	5/0662 {Stem cells}
5/0627 {Hair cells}	5/0663 {Bone marrow mesenchymal stem cells (BM-MSC)}
5/0628 {Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N 5/0666)}	5/0664 {Dental pulp stem cells, Dental follicle stem cells}
5/0629 {Keratinocytes; Whole skin}	5/0665 {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}
5/063 {Keratinocyte stem cells; Keratinocyte progenitors}	5/0666 {Mesenchymal stem cells from hair follicles}
5/0631 {Mammary cells}	5/0667 {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
5/0632 {Cells of the oral mucosa}	5/0668 {Mesenchymal stem cells from other natural sources}
5/0633 {Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands}	5/0669 {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647 , C12N 5/0663)}
5/0634 {Cells from the blood or the immune system}	5/067 {Hepatocytes}
NOTE Committed progenitors are classified with their progeny		5/0671 {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
5/0635 {B lymphocytes}	5/0672 {Stem cells; Progenitor cells; Precursor cells; Oval cells}
5/0636 {T lymphocytes}	5/0676 {Pancreatic cells}
5/0637 {Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)}	5/0677 {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
5/0638 {Cytotoxic T lymphocytes [CTL], lymphokine activated killer cells [LAK]}	5/0678 {Stem cells; Progenitor cells; Precursor cells}
5/0639 {Dendritic cells, e.g. Langerhans cells in the epidermis}	5/0679 {Cells of the gastro-intestinal tract}
5/064 {Immunosuppressive dendritic cells}	5/068 {Stem cells; Progenitors}
5/0641 {Erythrocytes}	5/0681 {Cells of the genital tract; Non-germinal cells from gonads}
		5/0682 {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0609)}
		5/0683 {Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/061)}

- 5/0684 . . . {Cells of the urinary tract or kidneys}
- 5/0685 {Bladder epithelial cells}
- 5/0686 {Kidney cells}
- 5/0687 {Renal stem cells; Renal progenitors}
- 5/0688 . . . {Cells from the lungs or the respiratory tract}
- 5/0689 {Stem cells; Progenitors}
- 5/069 . . . {Vascular Endothelial cells}
- 5/0691 {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}
- 5/0692 {Stem cells; Progenitor cells; Precursor cells}
- 5/0693 . . . {Tumour cells; Cancer cells}
- 5/0694 {Cells of blood, e.g. leukemia cells, myeloma cells}
- 5/0695 {Stem cells; Progenitor cells; Precursor cells}
- 5/0696 . . . {Artificially induced pluripotent stem cells, e.g. iPS}
- 5/0697 . . {Artificial constructs associating cells of different lineages, e.g. tissue equivalents ([blood vessels C12N 5/0691](#))}
- 5/0698 . . . {Skin equivalents}
- 5/10 . Cells modified by introduction of foreign genetic material
- 5/12 . . Fused cells, e.g. hybridomas
- 5/14 . . . Plant cells
- 5/16 . . . Animal cells
- 5/163 {one of the fusion partners being a B or a T lymphocyte}
- 5/166 {resulting from interspecies fusion}
- 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof ([preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K 39/00](#))**
- WARNING**
- From March 15, 2012 groups [C12N 7/02](#) - [C12N 7/08](#) and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range [C12N 2710/00-C12N 2795/00](#).
- 7/02 . Recovery or purification
- 7/025 . . {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}
- 7/04 . Inactivation or attenuation; Producing viral sub-units
- 7/045 . . {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}
- 7/06 . . {Inactivation or attenuation} by chemical treatment
- 7/08 . . {Inactivation or attenuation} by serial passage of virus

9/00

Enzymes; Proenzymes; Compositions thereof ([preparations containing enzymes for cleaning teeth A61K 8/66, A61Q 11/00](#); [medicinal preparations containing enzymes or proenzymes A61K 38/43](#); [enzyme containing detergent compositions C11D](#); {enzymes with nucleic acid structure, e.g. ribozymes, [C12N 15/113](#)}); **Processes for preparing, activating, inhibiting, separating or purifying enzymes** ([preparation of malt C12C 1/00](#))

NOTE

Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.

- 9/0002 . {Antibodies with enzymatic activity, e.g. abzymes}
- 9/0004 . {Oxidoreductases (1.)}
- 9/0006 . . {acting on CH-OH groups as donors (1.1)}
- 9/0008 . . {acting on the aldehyde or oxo group of donors (1.2)}
- 9/001 . . . {acting on the CH-CH group of donors (1.3)}
- 9/0012 . . {acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)}
- 9/0014 {acting on the CH-NH₂ group of donors (1.4)}
- 9/0016 {with NAD or NADP as acceptor (1.4.1)}
- 9/0018 {Phenylalanine dehydrogenase (1.4.1.20)}
- 9/002 {with a cytochrome as acceptor (1.4.2)}
- 9/0022 {with oxygen as acceptor (1.4.3)}
- 9/0024 {D-Amino acid oxidase (1.4.3.3)}
- 9/0026 {acting on CH-NH groups of donors (1.5)}
- 9/0028 {with NAD or NADP as acceptor (1.5.1)}
- 9/003 {Dihydrofolate reductase [DHFR] (1.5.1.3)}
- 9/0032 {with oxygen as acceptor (1.5.3)}
- 9/0034 {Sarcosine oxidase (1.5.3.1)}
- 9/0036 {acting on NADH or NADPH (1.6)}
- 9/0038 {with a heme protein as acceptor (1.6.2)}
- 9/004 {Cytochrome-b5 reductase (1.6.2.2)}
- 9/0042 {NADPH-cytochrome P450 reductase (1.6.2.4)}
- 9/0044 {acting on other nitrogen compounds as donors (1.7)}
- 9/0046 {with oxygen as acceptor (1.7.3)}
- 9/0048 {Uricase (1.7.3.3)}
- 9/0051 . . {acting on a sulfur group of donors (1.8)}
- 9/0053 . . {acting on a heme group of donors (1.9)}
- 9/0055 . . {acting on diphenols and related substances as donors (1.10)}
- 9/0057 . . . {with oxygen as acceptor (1.10.3)}
- 9/0059 {Catechol oxidase (1.10.3.1), i.e. tyrosinase}
- 9/0061 {Laccase (1.10.3.2)}
- 9/0063 {Ascorbate oxidase (1.10.3.3)}
- 9/0065 . . {acting on hydrogen peroxide as acceptor (1.11)}
- 9/0067 . . {acting on hydrogen as donor (1.12)}
- 9/0069 . . {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
- 9/0071 . . {acting on paired donors with incorporation of molecular oxygen (1.14)}
- 9/0073 . . . {with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}
- 9/0075 {Nitric-oxide synthase (1.14.13.39)}

9/0077	. . . {with a reduced iron-sulfur protein as one donor (1.14.15)}	9/1235	. . . {Diphosphotransferases (2.7.6)}
9/0079 {Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)}	9/1241	. . . {Nucleotidyltransferases (2.7.7)}
9/0081 {Cholesterol monooxygenase (cytochrome P 450sc)(1.14.15.6)}	9/1247 {DNA-directed RNA polymerase (2.7.7.6)}
9/0083	. . . {Miscellaneous (1.14.99)}	9/1252 {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}
9/0085 {Steroid 17 alpha-monooxygenase (1.14.99.9)}	9/1258 {Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase}
9/0087 {Steroid 21-monooxygenase (1.14.99.10)}	9/1264 {DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase}
9/0089	. . {acting on superoxide as acceptor (1.15)}	9/127 {RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase}
9/0091	. . {oxidizing metal ions (1.16)}	9/1276 {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
9/0093	. . {acting on CH or CH ₂ groups (1.17)}	9/1282 {RNA uridylyltransferase (2.7.7.52)}
9/0095	. . {acting on iron-sulfur proteins as donor (1.18)}	9/1288	. . . {Transferases for other substituted phosphate groups (2.7.8)}
9/0097	. . {acting on reduced flavodoxin as donor (1.19)}	9/1294	. . . {Phosphotransferases with paired acceptors (2.7.9)}
9/10	. Transferases (2.) (ribonucleases C12N 9/22)	9/13	. . {transferring sulfur containing groups (2.8)}
9/1003	. . {transferring one-carbon groups (2.1)}	9/14	. Hydrolases (3)
9/1007	. . . {Methyltransferases (general) (2.1.1.)}	9/16	. . acting on ester bonds (3.1)
9/1011 {Catechol O-methyltransferase (2.1.1.6)}	9/18	. . . Carboxylic ester hydrolases {(3.1.1)}
9/1014	. . . {Hydroxymethyl-, formyl-transferases (2.1.2)}	9/20 Triglyceride splitting, e.g. by means of lipase
9/1018	. . . {Carboxy- and carbamoyl transferases (2.1.3)}	9/22	. . . Ribonucleases {RNases, DNases (catalytic nucleic acids C12N 15/113)}
9/1022	. . {transferring aldehyde or ketonic groups (2.2)}	9/24	. . acting on glycosyl compounds (3.2)
9/1025	. . {Acytransferases (2.3)}	9/2402	. . . {hydrolysing O- and S- glycosyl compounds (3.2.1)}
9/1029	. . . {transferring groups other than amino-acyl groups (2.3.1)}	9/2405 {Glucanases}
9/1033 {Chloramphenicol O-acetyltransferase (2.3.1.28)}	9/2408 {acting on alpha -1,4-glucosidic bonds}
9/1037 {Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase}	9/2411 {Amylases}
9/104	. . . {Aminoacyltransferases (2.3.2)}	9/2414 {Alpha-amylase (3.2.1.1.)}
9/1044 {Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}	9/2417 {from microbiological source}
9/1048	. . {Glycosyltransferases (2.4)}	9/242 {Fungal source}
9/1051	. . . {Hexosyltransferases (2.4.1)}	9/2422 {from plant source}
9/1055 {Levansucrase (2.4.1.10)}	9/2425 {Beta-amylase (3.2.1.2)}
9/1059 {Cellulose synthases (2.4.1.12; 2.4.1.29)}	9/2428 {Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase}
9/1062 {Sucrose synthase (2.4.1.13)}	9/2431 {Beta-fructofuranosidase (3.2.1.26), i.e. invertase}
9/1066 {Sucrose phosphate synthase (2.4.1.14)}	9/2434 {acting on beta-1,4-glucosidic bonds}
9/107 {1,4-Alpha-glucan branching enzyme (2.4.1.18)}	9/2437 {Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)}
9/1074 {Cyclomaltodextrin glucanotransferase (2.4.1.19)}	9/244 {Endo-1,3(4)-beta-glucanase (3.2.1.6)}
9/1077	. . . {Pentosyltransferases (2.4.2)}	9/2442 {Chitinase (3.2.1.14)}
9/1081	. . . {transferring other glycosyl groups (2.4.99)}	9/2445 {Beta-glucosidase (3.2.1.21)}
9/1085	. . {transferring alkyl or aryl groups other than methyl groups (2.5)}	9/2448 {Licheninase (3.2.1.73)}
9/1088	. . . {Glutathione transferase (2.5.1.18)}	9/2451 {acting on alpha-1,6-glucosidic bonds}
9/1092	. . . {3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase}	9/2454 {Dextranase (3.2.1.11)}
9/1096	. . {transferring nitrogenous groups (2.6)}	9/2457 {Pullulanase (3.2.1.41)}
9/12	. . transferring phosphorus containing groups, e.g. kinases (2.7)	9/246 {Isoamylase (3.2.1.68)}
9/1205	. . . {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}	9/2462 {Lysozyme (3.2.1.17)}
9/1211 {Thymidine kinase (2.7.1.21)}	9/2465 {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
9/1217	. . . {Phosphotransferases with a carboxyl group as acceptor (2.7.2)}	9/2468 {acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)}
9/1223	. . . {Phosphotransferases with a nitrogenous group as acceptor (2.7.3)}	9/2471 {Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase}
9/1229	. . . {Phosphotransferases with a phosphate group as acceptor (2.7.4)}	9/2474 {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase}
		9/2477 {Hemicellulases not provided in a preceding group}

- 9/248 {Xylanases}
- 9/2482 {Endo-1,4-beta-xylanase (3.2.1.8)}
- 9/2485 {Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase}
- 9/2488 {Mannanases}
- 9/2491 {Beta-mannosidase (3.2.1.25), i.e. mannanase}
- 9/2494 {Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase}
- 9/2497 . . . {hydrolysing N- glycosyl compounds (3.2.2)}
- 9/48 . . acting on peptide bonds (3.4)
- 9/485 . . . {Exopeptidases (3.4.11-3.4.19)}
- 9/50 . . . Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)}

WARNING

Group [C12N 9/50](#) is impacted by reclassification into group [C12N 9/52](#).

Groups [C12N 9/50](#) and [C12N 9/52](#) should be considered in order to perform a complete search.

- 9/503 {derived from viruses}
- 9/506 {derived from RNA viruses}
- 9/52 derived from bacteria {or Archaea}

NOTE

{In this group, Archaea, formerly known as Archaeobacteria, are classified with bacteria.}

WARNING

Group [C12N 9/52](#) is incomplete pending reclassification of documents from group [C12N 9/50](#).

Groups [C12N 9/50](#) and [C12N 9/52](#) should be considered in order to perform a complete search.

- 9/54 bacteria being Bacillus
- 9/58 derived from fungi
- 9/60 from yeast
- 9/62 from Aspergillus
- 9/63 {derived from plants}
- 9/64 derived from animal tissue
- 9/6402 {from non-mammals}
- 9/6405 {not being snakes}
- 9/6408 {Serine endopeptidases (3.4.21)}
- 9/641 {Cysteine endopeptidases (3.4.22)}
- 9/6413 {Aspartic endopeptidases (3.4.23)}
- 9/6416 {Metalloendopeptidases (3.4.24)}
- 9/6418 {from snakes}
- 9/6421 {from mammals}
- 9/6424 {Serine endopeptidases (3.4.21)}
- 9/6427 {Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)}
- 9/6429 {Thrombin (3.4.21.5)}
- 9/6432 {Coagulation factor Xa (3.4.21.6)}
- 9/6435 {Plasmin (3.4.21.7), i.e. fibrinolysin}
- 9/6437 {Coagulation factor VIIa (3.4.21.21)}
- 9/644 {Coagulation factor IXa (3.4.21.22)}
- 9/6443 {Coagulation factor XIa (3.4.21.27)}
- 9/6445 {Kallikreins (3.4.21.34; 3.4.21.35)}

- 9/6448 {Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)}
- 9/6451 {Coagulation factor XIIa (3.4.21.38)}
- 9/6454 {Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases}
- 9/6456 {Plasminogen activators}
- 9/6459 {t-plasminogen activator (3.4.21.68), i.e. tPA}
- 9/6462 {u-Plasminogen activator (3.4.21.73), i.e. urokinase}
- 9/6464 {Protein C (3.4.21.69)}
- 9/6467 {Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)}
- 9/647 {Blood coagulation factors not provided for in a preceding group or according to more than one of the preceding groups}
- 9/6472 {Cysteine endopeptidases (3.4.22)}
- 9/6475 {Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)}
- 9/6478 {Aspartic endopeptidases (3.4.23)}
- 9/6481 {Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)}
- 9/6483 {Chymosin (3.4.23.4), i.e. rennin}
- 9/6486 {Renin (3.4.23.15)}
- 9/6489 {Metalloendopeptidases (3.4.24)}
- 9/6491 {Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)}
- 9/6494 {Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11}
- 9/6497 {Endothelin-converting enzyme (3.4.24.71)}
- 9/78 . . acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- 9/80 . . . acting on amide bonds in linear amides {(3.5.1)}
- 9/82 Asparaginase {(3.5.1.1)}
- 9/84 Penicillin amidase {(3.5.1.11)}
- 9/86 . . . acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}
- 9/88 . Lyases (4.)
- 9/90 . Isomerases (5.)
- 9/92 . . Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)}
- 9/93 . {Ligases (6)}
- 9/94 . Pancreatin
- 9/96 . Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- 9/98 . Preparation of granular or free-flowing enzyme compositions ([C12N 9/96 takes precedence](#))
- 9/99 . Enzyme inactivation by chemical treatment

11/00 Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof

- 11/02 . Enzymes or microbial cells immobilised on or in an organic carrier

- 11/04 . . . entrapped within the carrier, e.g. gel or hollow fibres
- 11/06 . . . attached to the carrier via a bridging agent
- 11/08 . . . the carrier being a synthetic polymer

WARNING

Group [C12N 11/08](#) is impacted by reclassification into groups [C12N 11/082](#), [C12N 11/084](#), [C12N 11/087](#), [C12N 11/089](#), [C12N 11/091](#), [C12N 11/093](#), [C12N 11/096](#), and [C12N 11/098](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 11/082 obtained by reactions only involving carbon-to-carbon unsaturated bonds

WARNING

Groups [C12N 11/082](#), [C12N 11/084](#), and [C12N 11/087](#) are incomplete pending reclassification of documents from group [C12N 11/08](#).

Groups [C12N 11/08](#), [C12N 11/082](#), [C12N 11/084](#) and [C12N 11/087](#) should be considered in order to perform a complete search.

- 11/084 Polymers containing vinyl alcohol units
- 11/087 Acrylic polymers
- 11/089 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

WARNING

Groups [C12N 11/089](#), [C12N 11/091](#), [C12N 11/093](#) and [C12N 11/096](#) are incomplete pending reclassification of documents from group [C12N 11/08](#).

Groups [C12N 11/08](#), [C12N 11/089](#), [C12N 11/091](#), [C12N 11/093](#) and [C12N 11/096](#) should be considered in order to perform a complete search.

- 11/091 Phenol resins; Amino resins
- 11/093 Polyurethanes
- 11/096 Polyesters; Polyamides
- 11/098 formed in the presence of the enzymes or microbial cells

WARNING

Group [C12N 11/098](#) is incomplete pending reclassification of documents from group [C12N 11/08](#).

Groups [C12N 11/08](#) and [C12N 11/098](#) should be considered in order to perform a complete search.

- 11/10 . . . the carrier being a carbohydrate
- 11/12 . . . Cellulose or derivatives thereof
- 11/14 . . Enzymes or microbial cells immobilised on or in an inorganic carrier
- 11/16 . . Enzymes or microbial cells immobilised on or in a biological cell
- 11/18 . . Multi-enzyme systems

13/00 Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

15/00 Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se [C12N 1/00](#), [C12N 5/00](#), [C12N 7/00](#); new plants per se [A01H](#); plant reproduction by tissue culture techniques [A01H 4/00](#); new animals per se [A01K 67/00](#); use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy [A61K 48/00](#))

- 15/01 . Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
- 15/02 . Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies [C07K 16/00](#); apparatus for cell fusion [C12M](#))}
- 15/03 . . Bacteria
- 15/04 . . Fungi
- 15/09 . Recombinant DNA-technology
- 15/10 . . Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA [C07H 21/00](#); preparation of non-structural polynucleotides from microorganisms or with enzymes [C12P 19/34](#))

NOTE

After the symbol [C12N 15/10](#) - [C12N 15/1096](#), and separated therefrom by a + sign, it is desirable to add the indexing codes selected from groups [C12Q 2500/00](#) - [C12Q 2565/634](#), relating to relevant technical features of the invention. When more than one indexing code is selected, the different codes are separated by a + sign. Example : [C12N 15/1037](#) + [C12Q 2537/125](#) + [C12Q 2521/537](#)

- 15/1003 . . . {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- 15/1006 {by means of a solid support carrier, e.g. particles, polymers}
- 15/101 {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
- 15/1013 {by using magnetic beads}
- 15/1017 {by filtration, e.g. using filters, frits, membranes}
- 15/102 . . . {Mutagenizing nucleic acids}
- 15/1024 {*In vivo* mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}
- 15/1027 {by DNA shuffling, e.g. RSR, STEP, RPR}
- 15/1031 {mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}
- 15/1034 . . . {Isolating an individual clone by screening libraries}

- 15/1037 {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- 15/1041 {Ribosome/Polysome display, e.g. SPERT, ARM}
- 15/1044 {Preparation or screening of libraries displayed on scaffold proteins}
- 15/1048 {SELEX}
- 15/1051 {Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
- 15/1055 {Protein x Protein interaction, e.g. two hybrid selection}
- 15/1058 {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- 15/1062 {mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
- 15/1065 {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- 15/1068 {Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatic DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
- 15/1072 {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- 15/1075 {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- 15/1079 {Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays [C12N 15/1086](#))}
- 15/1082 {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- 15/1086 {Preparation or screening of expression libraries, e.g. reporter assays}
- 15/1089 {Design, preparation, screening or analysis of libraries using computer algorithms}
- 15/1093 {General methods of preparing gene libraries, not provided for in other subgroups}
- 15/1096 . . . {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
- 15/11 . . DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, [C07H 21/00](#)); {Non-coding nucleic acids having a biological activity}
- NOTE**
- Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups
- [C12N 15/11](#) - [C12N 15/117](#) cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The [C12N 2303/00](#) ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group [C12N 15/111](#)
- 15/111 . . . {General methods applicable to biologically active non-coding nucleic acids}
- 15/113 . . . Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants [C12N 15/8218](#))}
- 15/1131 {against viruses}
- 15/1132 {against retroviridae, e.g. HIV}
- 15/1133 {against herpesviridae, e.g. HSV}
- 15/1135 {against oncogenes or tumor suppressor genes}
- 15/1136 {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- 15/1137 {against enzymes (viral enzymes [C12N 15/1131](#); receptors [C12N 15/1138](#))}
- 15/1138 {against receptors or cell surface proteins}
- 15/115 . . . Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith (; Nucleic acids binding to non-nucleic acids, e.g. aptamers)
- NOTE**
- Aptamers fused to compounds which are already classified in groups [C12N 15/11](#) - [C12N 15/117](#), are classified with the corresponding compound
- 15/117 . . . Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- 15/52 . . . Genes encoding for enzymes or proenzymes
- NOTE**
- In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.
- 15/62 . . . DNA sequences coding for fusion proteins
- NOTE**
- In this group, the following term is used with the meaning indicated:
- "fusion" means the fusion of two different proteins.
- 15/625 {containing a sequence coding for a signal sequence}
- 15/63 . . Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- 15/635 . . . {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracycline}

- 15/64 . . . General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- 15/65 . . . using markers ([enzymes used as markers C12N 15/52](#))
- 15/66 . . . General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

NOTE

In this group, the following expression is used with the meaning indicated:

- "non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.

- 15/67 . . . General methods for enhancing the expression
- 15/68 Stabilisation of the vector
- 15/69 Increasing the copy number of the vector
- 15/70 . . . Vectors or expression systems specially adapted for E. coli

NOTES

1. This group covers the use of E. coli as host.
2. Shuttle vectors also replicating in E. coli are classified according to the other host.

- 15/71 Expression systems using regulatory sequences derived from the trp-operon
- 15/72 Expression systems using regulatory sequences derived from the lac-operon
- 15/73 Expression systems using phage (lambda) regulatory sequences
- 15/74 . . . Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

NOTE

This group covers the use of prokaryotes as hosts.

- 15/743 {for Agrobacterium; Rhizobium; Bradyrhizobium}
- 15/746 {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}
- 15/75 for Bacillus
- 15/76 for Actinomyces; for Streptomyces
- 15/77 for Corynebacterium; for Brevibacterium
- 15/78 for Pseudomonas
- 15/79 . . . Vectors or expression systems specially adapted for eukaryotic hosts

NOTE

This group covers the use of eukaryotes as hosts.

- 15/80 for fungi
- 15/81 for yeasts
- 15/815 {for yeasts other than Saccharomyces}

- 15/82 for plant cells {, e.g. plant artificial chromosomes (PACs)}

WARNING

Documents are being continuously reclassified into this new classification scheme. See Warning notes below

- 15/8201 {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}
- 15/8202 {by biological means, e.g. cell mediated or natural vector}
- 15/8203 {Virus mediated transformation}
- 15/8205 {Agrobacterium mediated transformation}
- 15/8206 {by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated}
- 15/8207 {by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers}
- 15/8209 {Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers}

NOTE

Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in [C12N 15/8209](#)

- 15/821 {Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}
- 15/8212 {Colour markers, e.g. beta-glucuronidase [GUS], green fluorescent protein [GFP], carotenoid}
- 15/8213 {Targeted insertion of genes into the plant genome by homologous recombination}
- 15/8214 {Plastid transformation}
- 15/8216 {Methods for controlling, regulating or enhancing expression of transgenes in plant cells}
- 15/8217 {Gene switch}
- 15/8218 {Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}
- 15/822 {Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression}
- 15/8221 {Transit peptides}
- 15/8222 {Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation}
- 15/8223 {Vegetative tissue-specific promoters}
- 15/8225 {Leaf-specific, e.g. including petioles, stomata}

15/8226	{Stem-specific, e.g. including tubers, beets}	15/8267	{Seed dormancy, germination or sprouting}
15/8227	{Root-specific}	15/8269	{Photosynthesis}
15/8229	{Meristem-specific, e.g. nodal, apical}	15/827	{Flower development or morphology, e.g. flowering promoting factor [FPF]}
15/823	{Reproductive tissue-specific promoters}	15/8271	{for stress resistance, e.g. heavy metal resistance}
15/8231	{Male-specific, e.g. anther, tapetum, pollen}	15/8273	{for drought, cold, salt resistance}
15/8233	{Female-specific, e.g. pistil, ovule}	15/8274	{for herbicide resistance}
15/8234	{Seed-specific, e.g. embryo, endosperm}	15/8275	{Glyphosate}
15/8235	{Fruit-specific}	15/8277	{Phosphinotricin}
15/8237	{Externally regulated expression systems}	15/8278	{Sulfonylurea}
15/8238	{chemically inducible, e.g. tetracycline}	15/8279	{for biotic stress resistance, pathogen resistance, disease resistance}
15/8239	{pathogen inducible}	15/8281	{for bacterial resistance}
15/8241	{Phenotypically and genetically modified plants via recombinant DNA technology}	15/8282	{for fungal resistance}
15/8242	{with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}	15/8283	{for virus resistance}
15/8243	{involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}	15/8285	{for nematode resistance}
15/8245	{involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}	15/8286	{for insect resistance}
15/8246	{Non-starch polysaccharides, e.g. cellulose, fructans, levans}	15/8287	{for fertility modification, e.g. apomixis}
15/8247	{involving modified lipid metabolism, e.g. seed oil composition}	15/8289	{Male sterility}
15/8249	{involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life}	15/829	{Female sterility}
15/825	{involving pigment biosynthesis}	15/8291	{Hormone-influenced development}
NOTE			15/8293	{Absciscic acid [ABA]}
Transgenic plants with altered flower morphology are also classified in this group			15/8294	{Auxins}
15/8251	{Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}	15/8295	{Cytokinins}
15/8253	{Methionine or cysteine}	15/8297	{Gibberellins; GA3}
15/8254	{Tryptophan or lysine}	15/8298	{Brassinosteroids}
15/8255	{involving lignin biosynthesis}	15/85	for animal cells
15/8257	{for the production of primary gene products, e.g. pharmaceutical products, interferon}	15/8509	{for producing genetically modified animals, e.g. transgenic}
15/8258	{for the production of oral vaccines (antigens) or immunoglobulins}	NOTE		
15/8259	{Phytoremediation}	Additional aspects of the modified animals are classified in the groups A01K 2207/00 - A01K 2267/00		
15/8261	{with agronomic (input) traits, e.g. crop yield}	2015/8518	{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
15/8262	{involving plant development}	2015/8527	{for producing animal models, e.g. for tests or diseases}
15/8263	{Ablation; Apoptosis}	2015/8536	{Animal models for genetic diseases}
15/8265	{Transgene containment, e.g. gene dispersal}	2015/8545	{for Alzheimer's disease}
15/8266	{Abscission; Dehiscence; Senescence}	2015/8554	{Invertebrates models for Alzheimer's disease}
			2015/8563	{for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}
			2015/8572	{Animal models for proliferative diseases, e.g. comprising an oncogene}
			2015/8581	{Animal models for infectious diseases, e.g. AIDS}
			2015/859	{Animal models comprising reporter system for screening tests}

15/86	Viral vectors		2310/00	Structure or type of the nucleic acid
		WARNING		2310/10	. Type of nucleic acid
		From March 15, 2012 groups C12N 15/861 - C12N 15/869 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00-C12N 2795/00		2310/11	. . Antisense
15/861	Adenoviral vectors		2310/111	. . . spanning the whole gene, or a large part of it
15/8613	{Chimaeric vector systems comprising heterologous sequences for production of another viral vector}		2310/113	. . . targeting other non-coding nucleic acids, e.g. antagomirs
15/8616	{Special methods for targeting systems}		2310/12	. . catalytic nucleic acids, e.g. ribozymes
15/863	Poxviral vectors, {e.g. entomopoxvirus}		2310/121	. . . Hammerhead
15/8633	{Avian poxviral vectors}		2310/122	. . . Hairpin
15/8636	{Vaccina virus vectors}		2310/123	. . . Hepatitis delta
15/864	Parvoviral vectors {, e.g. parvovirus, densovirus}		2310/124	. . . based on group I or II introns
15/8645	{Adeno-associated virus}		2310/1241 Tetrahymena
15/866	Baculoviral vectors		2310/126	. . . involving RNase P
15/867	Retroviral vectors		2310/127	. . . DNazymes
15/8673	{Special methods for packaging systems}		2310/128	. . . processing or releasing ribozyme
15/8676	{Special methods for targeting systems}		2310/13	. . Decoys
15/869	Herpesviral vectors		2310/14	. . interfering N.A.
15/8695	{Herpes simplex virus-based vectors}		2310/141	. . . MicroRNAs, miRNAs
15/87	. .	Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation		2310/15	. . Nucleic acids forming more than 2 strands, e.g. TFOs
15/873	. . .	Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos		2310/151	. . . more than 3 strands, e.g. tetrads, H-DNA
15/877	Techniques for producing new mammalian cloned embryos		2310/152	. . . on a single-stranded target, e.g. fold-back TFOs
15/8771	{Bovine embryos}		2310/153	. . . with the aid of a protein, e.g. recombinase
15/8772	{Caprine embryos}		2310/16	. . Aptamers
15/8773	{Ovine embryos}		2310/17	. . Immunomodulatory nucleic acids
15/8775	{Murine embryos}		2310/18	. . acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17)
15/8776	{Primate embryos}		2310/20	. . involving clustered regularly interspaced short palindromic repeats [CRISPRs]
15/8777	{Rabbit embryos}		2310/30	. Chemical structure
15/8778	{Swine embryos}		2310/31	. . of the backbone
15/88	. . .	using microencapsulation, e.g. using {amphiphile} liposome vesicle		2310/311	. . . Phosphotriesters
15/89	. . .	using microinjection		2310/312	. . . Phosphonates
15/895	{using biolistic methods}		2310/3125 Methylphosphonates
15/90	. . .	Stable introduction of foreign DNA into chromosome		2310/313	. . . Phosphorodithioates
15/902	{using homologous recombination}		2310/314	. . . Phosphoramidates
15/905	{in yeast}		2310/3145 with the nitrogen in 3' or 5'-position
15/907	{in mammalian cells}		2310/315	. . . Phosphorothioates
2303/00		Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids		2310/316	. . . Phosphonothioates
		NOTE		2310/317	. . . with an inverted bond, e.g. a cap structure
		Indexing codes of group C12N 2303/00 are only used in combination with group C12N 15/111		2310/318	. . . where the PO2 is completely replaced, e.g. MMI or formacetal
				2310/3181 Peptide nucleic acid, PNA
				2310/3183 Diol linkers, e.g. glycols or propanediols
				2310/319	. . . linked by 2'-5' linkages, i.e. having a free 3'-position
				2310/32	. . of the sugar
				2310/321	. . . 2'-O-R Modification
				2310/322	. . . 2'-R Modification
				2310/323	. . . modified ring structure
				2310/3231 having an additional ring, e.g. LNA, ENA
				2310/3233 Morpholino-type ring
				2310/3235 having the O of the ribose replaced by another atom
				2310/33	. . of the base
				2310/331	. . . Universal or degenerate base
				2310/332	. . . Abasic residue
				2310/333	. . . Modified A
				2310/334	. . . Modified C
				2310/3341 5-Methylcytosine
				2310/335	. . . Modified T or U
				2310/336	. . . Modified G

2310/337	. . . in alpha-anomeric form	2330/50	. Biochemical production, i.e. in a transformed host cell
2310/34	. . Spatial arrangement of the modifications	2330/51	. . Specially adapted vectors
2310/341	. . . Gapmers, i.e. of the type =====	2500/00	Specific components of cell culture medium
2310/342	. . . Hemimers, i.e. of the type =====	2500/02	. Atmosphere, e.g. low oxygen conditions
2310/343	. . . having patterns, e.g. =====	2500/05	. Inorganic components
2310/344	. . . Position-specific modifications, e.g. on every purine, at the 3'-end	2500/10	. . Metals; Metal chelators (cobalamine C12N 2500/38)
2310/345	. . . having at least two different backbone modifications	2500/12	. . . Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
2310/346	. . . having a combination of backbone and sugar modifications	2500/14 Calcium; Ca chelators; Calcitonin
2310/35	. . Nature of the modification	2500/16 Magnesium; Mg chelators
2310/351	. . . Conjugate	2500/20	. . . Transition metals
2310/3511 intercalating or cleaving agent	2500/22 Zinc; Zn chelators (insulin-zinc complexes C12N 2501/33)
2310/3513 Protein; Peptide	2500/24 Iron; Fe chelators; Transferrin
2310/3515 Lipophilic moiety, e.g. cholesterol	2500/25 Insulin-transferrin; Insulin-transferrin-selenium
2310/3517 Marker; Tag	2500/30	. Organic components (metal chelators C12N 2500/10 ; calcitonin C12N 2500/14 ; transferrin C12N 2500/24)
2310/3519 Fusion with another nucleic acid	2500/32	. . Amino acids
2310/352	. . . linked to the nucleic acid via a carbon atom	2500/33	. . . other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
2310/3521 Methyl	2500/34	. . Sugars
2310/3523 Allyl	2500/35	. . Polyols, e.g. glycerin, inositol
2310/3525 MOE, methoxyethoxy	2500/36	. . Lipids
2310/3527 Other alkyl chain	2500/38	. . Vitamins
2310/3529 Aromatic substituent	2500/40	. . Nucleotides, nucleosides, bases (cyclic nucleotides C12N 2501/01 , anti-neoplastic drugs C12N 2501/06)
2310/353	. . . linked to the nucleic acid via an atom other than carbon	2500/42	. . Organic phosphate, e.g. beta glycerophosphate
2310/3531 Hydrogen	2500/44	. . Thiols, e.g. mercaptoethanol
2310/3533 Halogen	2500/46	. . Amines, e.g. putrescine
2310/3535 Nitrogen	2500/50	. Soluble polymers, e.g. polyethyleneglycol [PEG]
2310/50	. Physical structure	2500/60	. Buffer, e.g. pH regulation, osmotic pressure
2310/51	. . in polymeric form, e.g. multimers, concatemers	2500/62	. . DMSO
2310/52	. . branched	2500/70	. Undefined extracts (conditioned medium C12N 2502/00)
2310/53	. . partially self-complementary or closed	2500/72	. . from bacteria
2310/531	. . . Stem-loop; Hairpin	2500/74	. . from fungi, e.g. yeasts
2310/532	. . . Closed or circular	2500/76	. . from plants
2310/533	. . . having a mismatch or nick in at least one of the strands	2500/78	. . from protozoa
2320/00	Applications; Uses	2500/80	. . from animals
2320/10	. in screening processes	2500/82	. . . from invertebrates
2320/11	. . for the determination of target sites, i.e. of active nucleic acids	2500/84	. . . from mammals
2320/12	. . in functional genomics, i.e. for the determination of gene function	2500/90	. Serum-free medium, which may still contain naturally-sourced components
2320/13	. . in a process of directed evolution, e.g. SELEX, acquiring a new function	2500/92	. . Medium free of human- or animal-derived components
2320/30	. Special therapeutic applications	2500/95	. . Protein-free medium and culture conditions
2320/31	. . Combination therapy	2500/98	. Xeno-free medium and culture conditions
2320/32	. . Special delivery means, e.g. tissue-specific	2500/99	. Serum-free medium
2320/33	. . Alteration of splicing		
2320/34	. . Allele or polymorphism specific uses		
2320/35	. . based on a specific dosage / administration regimen		
2320/50	. Methods for regulating/modulating their activity		
2320/51	. . modulating the chemical stability, e.g. nuclease-resistance		
2320/52	. . modulating the physical stability, e.g. GC-content		
2320/53	. . reducing unwanted side-effects		
2330/00	Production		
2330/10	. naturally occurring		
2330/30	. chemically synthesised		
2330/31	. . Libraries, arrays		

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 2500/90](#) - [C12N 2500/98](#)

2501/00	Active agents used in cell culture processes, e.g. differentiation		
	NOTE		
	Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in C07K 14/00 , but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.		
2501/01	• Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin	2501/195	• • Heregulin, neu differentiation factor
2501/02	• Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes	2501/20	• Cytokines; Chemokines
2501/03	• Compounds acting on the NO pathway, e.g. nitrososarginine	2501/21	• • Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
2501/04	• Immunosuppressors, e.g. cyclosporin, tacrolimus	2501/22	• • Colony stimulating factors (G-CSF, GM-CSF)
2501/05	• Adjuvants	2501/23	• • Interleukins [IL]
2501/051	• • Lipid A (MPA, MPL)	2501/2301	• • • Interleukin-1 (IL-1)
2501/052	• • Lipopolysaccharides [LPS]	2501/2302	• • • Interleukin-2 (IL-2)
2501/054	• • Muramyle peptides	2501/2303	• • • Interleukin-3 (IL-3)
2501/056	• • Immunostimulating oligonucleotides, e.g. CpG	2501/2304	• • • Interleukin-4 (IL-4)
2501/06	• Anti-neoplastic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide	2501/2305	• • • Interleukin-5 (IL-5)
2501/065	• Modulators of histone acetylation	2501/2306	• • • Interleukin-6 (IL-6)
2501/07	• Heat shock proteins	2501/2307	• • • Interleukin-7 (IL-7)
2501/10	• Growth factors	2501/2308	• • • Interleukin-8 (IL-8)
2501/105	• • Insulin-like growth factors [IGF]	2501/2309	• • • Interleukin-9 (IL-9)
2501/11	• • Epidermal growth factor [EGF]	2501/231	• • • Interleukin-10 (IL-10)
2501/113	• • Acidic fibroblast growth factor (aFGF, FGF-1)	2501/2311	• • • Interleukin-11 (IL-11)
2501/115	• • Basic fibroblast growth factor (bFGF, FGF-2)	2501/2312	• • • Interleukin-12 (IL-12)
2501/117	• • Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)	2501/2313	• • • Interleukin-13 (IL-13)
2501/119	• • Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10	2501/2314	• • • Interleukin-14 (IL-14)
2501/12	• • Hepatocyte growth factor [HGF]	2501/2315	• • • Interleukin-15 (IL-15)
2501/125	• • Stem cell factor [SCF], c-kit ligand [KL]	2501/2316	• • • Interleukin-16 (IL-16)
2501/13	• • Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins	2501/2317	• • • Interleukin-17 (IL-17)
2501/135	• • Platelet-derived growth factor [PDGF]	2501/2318	• • • Interleukin-18 (IL-18)
2501/14	• • Erythropoietin [EPO]	2501/2319	• • • Interleukin-19 (IL-19)
2501/145	• • Thrombopoietin [TPO]	2501/232	• • • Interleukin-20 (IL-20)
2501/148	• • Transforming growth factor alpha [TGF- α]	2501/2321	• • • Interleukin-21 (IL-21)
2501/15	• • Transforming growth factor beta (TGF- β)	2501/2322	• • • Interleukin-22 (IL-22)
2501/155	• • Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor	2501/2323	• • • Interleukin-23 (IL-23)
2501/16	• • Activin; Inhibin; Mullerian inhibiting substance	2501/2324	• • • Interleukin-24 (IL-24)
2501/165	• • Vascular endothelial growth factor [VEGF]	2501/2325	• • • Interleukin-25 (IL-25)
2501/17	• • Angiopoietin	2501/2326	• • • Interleukin-26 (IL-26)
2501/175	• • Cardiotrophin	2501/2327	• • • Interleukin-27 (IL-27)
2501/18	• • Liver cell growth factor (LCGF, Gly-His-Lys)	2501/2328	• • • Interleukin-28 (IL-28)
2501/185	• • Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)	2501/2329	• • • Interleukin-29 (IL-29)
2501/19	• • Growth and differentiation factors [GDF]	2501/233	• • • Interleukin-30 (IL-30)
		2501/2331	• • • Interleukin-31 (IL-31)
		2501/2332	• • • Interleukin-32 (IL-32)
		2501/2333	• • • Interleukin-33 (IL-33)
		2501/2334	• • • Interleukin-34 (IL-34)
		2501/2335	• • • Interleukin-35 (IL-35)
		2501/235	• • • Leukemia inhibitory factor [LIF]
		2501/237	• • Oncostatin M [OSM]
		2501/24	• • Interferons [IFN]
		2501/25	• • Tumour necrosing factors [TNF]
		2501/26	• • Flt-3 ligand (CD135L, flk-2 ligand)
		2501/30	• Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85)
		2501/305	• • Growth hormone [GH], aka. somatotropin
		2501/31	• • Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
		2501/315	• • Prolactin
		2501/32	• • Angiotensins [AT], angiotensinogen
		2501/33	• • Insulin (together with transferrin C12N 2500/25 ; Insulin-like growth factors C12N 2501/105)
		2501/335	• • Glucagon; Glucagon-like peptide [GLP]; Exendin
		2501/34	• • Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin
		2501/345	• • Gastrin; Cholecystokinins [CCK]

2501/35	. . Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]	2501/855	. . Corticotropin [ACTH]
2501/355	. . Leptin	2501/86	. . Melanocyte-stimulating hormone [MSH]
2501/36	. . Somatostatin	2501/90	. Polysaccharides
2501/365	. . Endothelin	2501/905	. . Hyaluronic acid
2501/37	. . Parathyroid hormone [PTH]	2501/91	. . Heparin
2501/375	. . Thyroid stimulating hormone [TSH]	2501/998	. Proteins not provided for elsewhere
2501/38	. . with nuclear receptors	NOTE	
2501/385	. . . of the family of the retinoic acid receptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]	Classification by pathway does not apply.	
2501/39	. . . Steroid hormones	2501/999	. Small molecules not provided for elsewhere
2501/392	. . . Sexual steroids	NOTE	
2501/395	. . . Thyroid hormones	Classification by pathway does not apply.	
2501/40	. Regulators of development	2502/00	Coculture with; Conditioned medium produced by
2501/405	. . Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases	2502/02	. embryonic cells
2501/41	. . Hedgehog proteins; Cyclopamine (inhibitor)	2502/025	. . extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
2501/415	. . Wnt; Frizzled	2502/03	. non-embryonic pluripotent stem cells
2501/42	. . Notch; Delta; Jagged; Serrate	2502/04	. germ cells
2501/48	. . Regulators of apoptosis	2502/07	. endocrine cells
2501/50	. Cell markers; Cell surface determinants	2502/072	. . adrenal cells
2501/505	. . CD4; CD8	2502/074	. . pinealocytes
2501/51	. . B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)	2502/076	. . pituitary cells
2501/515	. . CD3, T-cell receptor complex	2502/078	. . thyroid, parathyroid cells
2501/52	. . CD40, CD40-ligand (CD154)	2502/08	. cells of the nervous system
2501/53	. . CD2	2502/081	. . neurons
2501/58	. . Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)	2502/083	. . sensory transducers
2501/585	. . Integrins	2502/085	. . eye cells
2501/59	. . Lectins	2502/086	. . glial cells
2501/599	. . with CD designations not provided for elsewhere	2502/088	. . neural stem cells
2501/60	. Transcription factors	2502/09	. epidermal cells, skin cells, oral mucosa cells
2501/602	. . Sox-2	2502/091	. . melanocytes
2501/603	. . Oct-3/4	2502/092	. . hair cells
2501/604	. . Klf-4	2502/094	. . keratinocytes
2501/605	. . Nanog	2502/095	. . mammary cells
2501/606	. . c-Myc	2502/097	. . oral mucosa cells
2501/608	. . Lin28	2502/098	. . cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands
2501/65	. MicroRNA	2502/11	. blood or immune system cells
2501/70	. Enzymes	2502/1107	. . B cells
2501/71	. . Oxidoreductases (EC 1.)	2502/1114	. . T cells
2501/72	. . Transferases (EC 2.) (acetylation of histones C12N 2501/065)	2502/1121	. . Dendritic cells
2501/724	. . . Glycosyltransferases (EC 2.4.)	2502/1128	. . Erythrocytes
2501/727	. . . Kinases (EC 2.7.)	2502/1135	. . Granulocytes
2501/73	. . Hydrolases (EC 3.)	2502/1142	. . Osteoclasts
2501/734	. . . Proteases (EC 3.4.)	2502/115	. . Platelets, megakaryocytes
2501/80	. Neurotransmitters; Neurohormones	2502/1157	. . Monocytes, macrophages
2501/805	. . Acetylcholine	2502/1164	. . NK cells
2501/81	. . Adrenaline	2502/1171	. . Haematopoietic stem cells
2501/815	. . Dopamine	2502/1178	. . Spleen cells
2501/82	. . Histamine	2502/1185	. . Thymus cells
2501/825	. . Serotonine (5-HT); Melatonin	2502/1192	. . Lymphatic cells
2501/83	. . Tachykinins, e.g. substance P	2502/13	. connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
2501/835	. . Neuropeptide Y [NPY]; Peptide YY [PYY]	2502/1305	. . Adipocytes
2501/84	. . Excitatory amino acids	2502/1311	. . Osteocytes, osteoblasts, odontoblasts
2501/845	. . Gamma amino butyric acid [GABA]	2502/1317	. . Chondrocytes
2501/85	. Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin	2502/1323	. . Adult fibroblasts
		2502/1329	. . Cardiomyocytes
		2502/1335	. . Skeletal muscle cells, myocytes, myoblasts, myotubes

2502/1341	. . Tenocytes, cells from tendons and ligaments	2506/08	. from cells of the nervous system
2502/1347	. . Smooth muscle cells	2506/09	. from epidermal cells, from skin cells, from oral mucosa cells
2502/1352	. . Mesenchymal stem cells	2506/091	. . from melanocytes
2502/1358	. . . Bone marrow mesenchymal stem cells (BM- MSC)	2506/092	. . from hair cells
2502/1364	. . . Dental pulp stem cells, dental follicle stem cells	2506/094	. . from keratinocytes
2502/137	. . . Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood	2506/095	. . from mammary cells
2502/1376	. . . Mesenchymal stem cells from hair follicles	2506/097	. . from oral mucosa cells
2502/1382	. . . Adipose-derived stem cells [ADSC], adipose stromal stem cells	2506/098	. . from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands
2502/1388	. . . Mesenchymal stem cells from other natural sources	2506/11	. from blood or immune system cells
2502/1394	. . Bone marrow stromal cells; whole marrow	2506/115	. . from monocytes, from macrophages
2502/14	. hepatocytes	2506/13	. from connective tissue cells, from mesenchymal cells
2502/22	. pancreatic cells	2506/1307	. . from adult fibroblasts
2502/23	. Gastro-intestinal tract cells	2506/1315	. . from cardiomyocytes
2502/24	. Genital tract cells, non-germinal cells from gonads	2506/1323	. . from skeletal muscle cells
2502/243	. . Cells of the female genital tract, non-germinal ovarian cells	2506/133	. . from tenocytes
2502/246	. . Cells of the male genital tract, non-germinal testis cells	2506/1338	. . from smooth muscle cells
2502/25	. Urinary tract cells, renal cells	2506/1346	. . from mesenchymal stem cells
2502/253	. . Bladder cells	2506/1353	. . . from bone marrow mesenchymal stem cells (BM-MSC)
2502/256	. . Renal cells	2506/1361	. . . from dental pulp or dental follicle stem cells
2502/27	. Lung cells, respiratory tract cells	2506/1369	. . . from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
2502/28	. Vascular endothelial cells	2506/1376	. . . from mesenchymal stem cells derived from hair follicles
2502/30	. tumour cells	2506/1384	. . . from adipose-derived stem cells [ADSC], from adipose stromal stem cells
2502/45	. Artificially induced pluripotent stem cells	2506/1392	. . . from mesenchymal stem cells from other natural sources
2502/50	. invertebrate cells	2506/14	. from hepatocytes
2502/70	. Non-animal cells	2506/22	. from pancreatic cells
2502/99	. genetically modified cells	2506/23	. from cells of the gastro-intestinal tract
		2506/24	. from cells of the genital tract, from non-germinal gonad cells
		2506/243	. . from cells of the female genital tract cells, from non-germinal ovarian cells
		2506/246	. . from cells of the male genital tract cells, from non-germinal testis cells
		2506/25	. from renal cells, from cells of the urinary tract
		2506/27	. from lung cells, from cells of the respiratory tract
		2506/28	. from vascular endothelial cells
		2506/30	. from cancer cells, e.g. reversion of tumour cells

NOTE

Use [C12N 2501/00](#) to index the expressed products.

2503/00	Use of cells in diagnostics
2503/02	. Drug screening
2503/04	. Screening or testing on artificial tissues
2503/06	. . Screening or testing on artificial skin
2506/00	Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells

NOTE

This scheme indexes the starting point of a differentiation process and is used in combination with classification in [C12N 5/06](#) for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

2506/02	. from embryonic cells
2506/025	. . from extra-embryonic cells, e.g. trophoblast, placenta
2506/03	. from non-embryonic pluripotent stem cells
2506/04	. from germ cells
2506/07	. from endocrine cells
2506/072	. . from adrenal cells
2506/074	. . from pinealocytes
2506/076	. . from pituitary cells
2506/078	. . from thyroid, parathyroid cells

NOTE

Unless the tumourigenic phenotype is totally reversed, the end product is still classified under [C12N 5/0693](#).

2506/45	. from artificially induced pluripotent stem cells
2509/00	Methods for the dissociation of cells, e.g. specific use of enzymes
2509/10	. Mechanical dissociation
2510/00	Genetically modified cells
2510/02	. Cells for production
2510/04	. Immortalised cells
2511/00	Cells for large scale production
2513/00	3D culture
2517/00	Cells related to new breeds of animals
2517/02	. Cells from transgenic animals

- 2517/04 . Cells produced using nuclear transfer
- 2517/10 . Conditioning of cells for in vitro fecondation or nuclear transfer
- 2521/00 Culture process characterised by the use of hydrostatic pressure, flow or shear forces**
- 2521/10 . Sound, e.g. ultrasounds
- 2523/00 Culture process characterised by temperature**
- 2525/00 Culture process characterised by gravity, e.g. microgravity**
- 2527/00 Culture process characterised by the use of mechanical forces, e.g. strain, vibration**
- 2529/00 Culture process characterised by the use of electromagnetic stimulation**
- 2529/10 . Stimulation by light
- 2531/00 Microcarriers**
- 2533/00 Supports or coatings for cell culture, characterised by material**
- 2533/10 . Mineral substrates
- 2533/12 . . Glass
- 2533/14 . . Ceramic
- 2533/18 . . Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
- 2533/20 . Small organic molecules
- 2533/30 . Synthetic polymers ([thermoreactive polymers, e.g. PNIPAm, C12N 2539/10](#))
- 2533/32 . . Polylysine, polyornithine
- 2533/40 . . Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
- 2533/50 . Proteins
- 2533/52 . . Fibronectin; Laminin
- 2533/54 . . Collagen; Gelatin
- 2533/56 . . Fibrin; Thrombin
- 2533/70 . Polysaccharides
- 2533/72 . . Chitin, chitosan
- 2533/74 . . Alginate
- 2533/76 . . Agarose, agar-agar
- 2533/78 . . Cellulose
- 2533/80 . . Hyaluronan
- 2533/90 . Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- 2533/92 . . Amnion; Decellularised dermis or mucosa
- 2535/00 Supports or coatings for cell culture characterised by topography**
- 2535/10 . Patterned coating
- 2537/00 Supports and/or coatings for cell culture characterised by physical or chemical treatment**
- 2537/10 . Cross-linking
- 2539/00 Supports and/or coatings for cell culture characterised by properties**
- 2539/10 . Coating allowing for selective detachment of cells, e.g. thermoreactive coating
- 2700/00 Viruses**
- 2710/00 dsDNA Viruses ([not used](#))**
- 2710/00011 . dsDNA Viruses
- 2710/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/00023 . . Virus like particles [VLP]
- 2710/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/00041 . . Use of virus, viral particle or viral elements as a vector
- 2710/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/00043 . . . viral genome or elements thereof as genetic vector
- 2710/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/00045 . . . Special targeting system for viral vectors
- 2710/00051 . . Methods of production or purification of viral material
- 2710/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/00061 . . Methods of inactivation or attenuation
- 2710/00062 . . . by genetic engineering
- 2710/00063 . . . by chemical treatment
- 2710/00064 . . . by serial passage
- 2710/00071 . . Demonstrated in vivo effect
- 2710/00088 . . For redistribution
- 2710/10011 . . Adenoviridae
- 2710/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10023 . . . Virus like particles [VLP]
- 2710/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10043 viral genome or elements thereof as genetic vector
- 2710/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10045 Special targeting system for viral vectors

2710/10051	. . .	Methods of production or purification of viral material	2710/10234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10052	relating to complementing cells and packaging systems for producing virus or viral particles	2710/10241	Use of virus, viral particle or viral elements as a vector
2710/10061	. . .	Methods of inactivation or attenuation	2710/10242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10062	by genetic engineering	2710/10243	viral genome or elements thereof as genetic vector
2710/10063	by chemical treatment	2710/10244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10064	by serial passage	2710/10245	Special targeting system for viral vectors
2710/10071	. . .	Demonstrated <u>in vivo</u> effect	2710/10251	Methods of production or purification of viral material
2710/10088	. . .	For redistribution	2710/10252	relating to complementing cells and packaging systems for producing virus or viral particles
2710/10111	. . .	Adenovirus, e.g. ovine adenovirus D	2710/10261	Methods of inactivation or attenuation
2710/10121	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/10262	by genetic engineering
2710/10122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/10263	by chemical treatment
2710/10123	Virus like particles [VLP]	2710/10264	by serial passage
2710/10131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/10271	Demonstrated <u>in vivo</u> effect
2710/10132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/10288	For redistribution
2710/10133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/10311	. . .	Mastadenovirus, e.g. human or simian adenoviruses
2710/10134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/10321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10141	Use of virus, viral particle or viral elements as a vector	2710/10322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/10323	Virus like particles [VLP]
2710/10143	viral genome or elements thereof as genetic vector	2710/10331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/10332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10145	Special targeting system for viral vectors	2710/10333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10151	Methods of production or purification of viral material	2710/10334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10152	relating to complementing cells and packaging systems for producing virus or viral particles	2710/10341	Use of virus, viral particle or viral elements as a vector
2710/10161	Methods of inactivation or attenuation	2710/10342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10162	by genetic engineering	2710/10343	viral genome or elements thereof as genetic vector
2710/10163	by chemical treatment	2710/10344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10164	by serial passage	2710/10345	Special targeting system for viral vectors
2710/10171	Demonstrated <u>in vivo</u> effect	2710/10351	Methods of production or purification of viral material
2710/10188	For redistribution	2710/10352	relating to complementing cells and packaging systems for producing virus or viral particles
2710/10211	. . .	Aviadenovirus, e.g. fowl adenovirus A	2710/10361	Methods of inactivation or attenuation
2710/10221	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/10362	by genetic engineering
2710/10222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/10363	by chemical treatment
2710/10223	Virus like particles [VLP]	2710/10364	by serial passage
2710/10231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/10371	Demonstrated <u>in vivo</u> effect
2710/10232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/10388	For redistribution
2710/10233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/12011	. .	Asfarviridae

2710/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/12023	. . .	Virus like particles [VLP]
2710/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/12041	. . .	Use of virus, viral particle or viral elements as a vector
2710/12042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/12043	. . .	viral genome or elements thereof as genetic vector
2710/12044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/12045	. . .	Special targeting system for viral vectors
2710/12051	. . .	Methods of production or purification of viral material
2710/12052	. . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/12061	. . .	Methods of inactivation or attenuation
2710/12062	. . .	by genetic engineering
2710/12063	. . .	by chemical treatment
2710/12064	. . .	by serial passage
2710/12071	. . .	Demonstrated <u>in vivo</u> effect
2710/12088	. . .	For redistribution
2710/14011	. .	Baculoviridae
2710/14021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/14022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/14023	. . .	Virus like particles [VLP]
2710/14031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/14032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/14033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/14034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/14041	. . .	Use of virus, viral particle or viral elements as a vector
2710/14042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/14043	. . .	viral genome or elements thereof as genetic vectore
2710/14044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/14045	. . .	Special targeting system for viral vectors
2710/14051	. . .	Methods of production or purification of viral material
2710/14052	. . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/14061	. . .	Methods of inactivation or attenuation
2710/14062	. . .	by genetic engineering
2710/14063	. . .	by chemical treatment
2710/14064	. . .	by serial passage
2710/14071	. . .	Demonstrated <u>in vivo</u> effect
2710/14088	. . .	For redistribution
2710/14111	. . .	Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
2710/14121	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/14122	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/14123	. . .	Virus like particles [VLP]
2710/14131	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/14132	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/14133	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/14134	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/14141	. . .	Use of virus, viral particle or viral elements as a vector
2710/14142	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/14143	. . .	viral genome or elements thereof as genetic vector
2710/14144	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/14145	. . .	Special targeting system for viral vectors
2710/14151	. . .	Methods of production or purification of viral material
2710/14152	. . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/14161	. . .	Methods of inactivation or attenuation
2710/14162	. . .	by genetic engineering
2710/14163	. . .	by chemical treatment
2710/14164	. . .	by serial passage
2710/14171	. . .	Demonstrated <u>in vivo</u> effect
2710/14188	. . .	For redistribution
2710/16011	. .	Herpesviridae
2710/16021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16023	. . .	Virus like particles [VLP]
2710/16031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

2710/16034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/16221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16041	. . .	Use of virus, viral particle or viral elements as a vector	2710/16222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/16223	Virus like particles [VLP]
2710/16043	viral genome or elements thereof as genetic vector	2710/16231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/16232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16045	Special targeting system for viral vectors	2710/16233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16051	. . .	Methods of production or purification of viral material	2710/16234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16052	relating to complementing cells and packaging systems for producing virus or viral particles	2710/16241	Use of virus, viral particle or viral elements as a vector
2710/16061	. . .	Methods of inactivation or attenuation	2710/16242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16062	by genetic engineering	2710/16243	viral genome or elements thereof as genetic vector
2710/16063	by chemical treatment	2710/16244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16064	by serial passage	2710/16245	Special targeting system for viral vectors
2710/16071	. . .	Demonstrated <u>in vivo</u> effect	2710/16251	Methods of production or purification of viral material
2710/16088	. . .	For redistribution	2710/16252	relating to complementing cells and packaging systems for producing virus or viral particles
2710/16111	. . .	Cytomegalovirus, e.g. human herpesvirus 5	2710/16261	Methods of inactivation or attenuation
2710/16121	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/16262	by genetic engineering
2710/16122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/16263	by chemical treatment
2710/16123	Virus like particles [VLP]	2710/16264	by serial passage
2710/16131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/16271	Demonstrated <u>in vivo</u> effect
2710/16132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/16288	For redistribution
2710/16133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/16311	. . .	Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
2710/16134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/16321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16141	Use of virus, viral particle or viral elements as a vector	2710/16322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/16323	Virus like particles [VLP]
2710/16143	viral genome or elements thereof as genetic vector	2710/16331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/16332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16145	Special targeting system for viral vectors	2710/16333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16151	Methods of production or purification of viral material	2710/16334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16152	relating to complementing cells and packaging systems for producing virus or viral particles	2710/16341	Use of virus, viral particle or viral elements as a vector
2710/16161	Methods of inactivation or attenuation	2710/16342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16162	by genetic engineering	2710/16343	viral genome or elements thereof as genetic vector
2710/16163	by chemical treatment	2710/16344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16164	by serial passage			
2710/16171	Demonstrated <u>in vivo</u> effect			
2710/16188	For redistribution			
2710/16211	. . .	Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus			

2710/16345	Special targeting system for viral vectors	2710/16534	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral
2710/16351	Methods of production or purification of viral material	2710/16541	Use of virus, viral particle or viral elements as a vector
2710/16352	relating to complementin g cells and packaging systems for producing virus or viral particles	2710/16542	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16361	Methods of inactivation or attenuation	2710/16543	viral genome or elements thereof as genetic vector
2710/16362	by genetic engineering	2710/16544	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16363	by chemical treatment	2710/16545	Special targeting system for viral vectors
2710/16364	by serial passage	2710/16551	Methods of production or purification of viral material
2710/16371	Demonstrated <u>in vivo</u> effect	2710/16552	relating to complementing cells and packaging systems for producing virus or viral particles
2710/16388	For redistribution	2710/16561	Methods of inactivation or attenuation
2710/16411	. . .	Rhadinovirus, e.g. human herpesvirus 8	2710/16562	by genetic engineering
2710/16421	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/16563	by chemical treatment
2710/16422	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/16564	by serial passage
2710/16423	Virus like particles [VLP]	2710/16571	Demonstrated <u>in vivo</u> effect
2710/16431	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/16588	For redistribution
2710/16432	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/16611	. . .	Simplexvirus, e.g. human herpesvirus 1, 2
2710/16433	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/16621	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16434	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/16622	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16441	Use of virus, viral particle or viral elements as a vector	2710/16623	Virus like particles [VLP]
2710/16442	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/16631	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16443	viral genome or elements thereof as genetic vector	2710/16632	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16444	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/16633	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16445	Special targeting system for viral vectors	2710/16634	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16451	Methods of production or purification of viral material	2710/16641	Use of virus, viral particle or viral elements as a vector
2710/16452	relating to complementing cells and packaging systems for producing virus or viral particles	2710/16642	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16461	Methods of inactivation or attenuation	2710/16643	viral genome or elements thereof as genetic vector
2710/16462	by genetic engineering	2710/16644	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16463	by chemical treatment	2710/16645	Special targeting system for viral vectors
2710/16464	by serial passage	2710/16651	Methods of production or purification of viral material
2710/16471	Demonstrated <u>in vivo</u> effect	2710/16652	relating to complementing cells and packaging systems for producing virus or viral particles
2710/16488	For redistribution	2710/16661	Methods of inactivation or attenuation
2710/16511	. . .	Roseolovirus, e.g. human herpesvirus 6, 7	2710/16662	by genetic engineering
2710/16521	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/16663	by chemical treatment
2710/16522	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/16664	by serial passage
2710/16523	Virus like particles [VLP]	2710/16671	Demonstrated <u>in vivo</u> effect
2710/16531	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/16688	For redistribution
2710/16532	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/16711	. . .	Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
2710/16533	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory			

2710/16721	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/18051	. . .	Methods of production or purification of viral material
2710/16722	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/18052	relating to complementing cells and packaging systems for producing virus or viral particles
2710/16723	Virus like particles [VLP]	2710/18061	. . .	Methods of inactivation or attenuation
2710/16731	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/18062	by genetic engineering
2710/16732	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/18063	by chemical treatment
2710/16733	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/18064	by serial passage
2710/16734	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/18071	. . .	Demonstrated <u>in vivo</u> effect
2710/16741	Use of virus, viral particle or viral elements as a vector	2710/18088	. . .	For redistribution
2710/16742	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/20011	. . .	Papillomaviridae
2710/16743	viral genome or elements thereof as genetic vector	2710/20021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16744	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/20022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16745	Special targeting system for viral vectors	2710/20023	. . .	Virus like particles [VLP]
2710/16751	Methods of production or purification of viral material	2710/20031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16752	relating to complementing cells and packaging systems for producing virus or viral particles	2710/20032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16761	Methods of inactivation or attenuation	2710/20033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16762	by genetic engineering	2710/20034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16763	by chemical treatment	2710/20041	. . .	Use of virus, viral particle or viral elements as a vector
2710/16764	by serial passage	2710/20042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16771	Demonstrated <u>in vivo</u> effect	2710/20043	viral genome or elements thereof as genetic vector
2710/16788	For redistribution	2710/20044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/18011	. . .	Nimaviridae	2710/20045	Special targeting system for viral vectors
2710/18021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/20051	. . .	Methods of production or purification of viral material
2710/18022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/20052	relating to complementing cells and packaging systems for producing virus or viral particles
2710/18023	. . .	Virus like particles [VLP]	2710/20061	. . .	Methods of inactivation or attenuation
2710/18031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/20062	by genetic engineering
2710/18032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/20063	by chemical treatment
2710/18033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/20064	by serial passage
2710/18034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/20071	. . .	Demonstrated <u>in vivo</u> effect
2710/18041	. . .	Use of virus, viral particle or viral elements as a vector	2710/20088	. . .	For redistribution
2710/18042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/22011	. . .	Polyomaviridae, e.g. polyoma, SV40, JC
2710/18043	viral genome or elements thereof as genetic vector	2710/22021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/18044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/22022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/18045	Special targeting system for viral vectors	2710/22023	. . .	Virus like particles [VLP]
			2710/22031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
			2710/22032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
			2710/22033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

2710/22034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/24121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/22041	. . .	Use of virus, viral particle or viral elements as a vector	2710/24122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/22042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/24123	Virus like particles [VLP]
2710/22043	viral genome or elements thereof as genetic vector	2710/24131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/22044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/24132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/22045	Special targeting system for viral vectors	2710/24133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/22051	. . .	Methods of production or purification of viral material	2710/24134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/22052	relating to complementing cells and packaging systems for producing virus or viral particles	2710/24141	Use of virus, viral particle or viral elements as a vector
2710/22061	. . .	Methods of inactivation or attenuation	2710/24142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/22062	by genetic engineering	2710/24143	viral genome or elements thereof as genetic vector
2710/22063	by chemical treatment	2710/24144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/22064	by serial passage	2710/24145	Special targeting system for viral vectors
2710/22071	. . .	Demonstrated <u>in vivo</u> effect	2710/24151	Methods of production or purification of viral material
2710/22088	. . .	For redistribution	2710/24152	relating to complementing cells and packaging systems for producing virus or viral particles
2710/24011	. .	Poxviridae	2710/24161	Methods of inactivation or attenuation
2710/24021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/24162	by genetic engineering
2710/24022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/24163	by chemical treatment
2710/24023	. . .	Virus like particles [VLP]	2710/24164	by serial passage
2710/24031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/24171	Demonstrated <u>in vivo</u> effect
2710/24032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/24188	For redistribution
2710/24033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/24211	. . .	Parapoxvirus, e.g. Orf virus
2710/24034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/24221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/24041	. . .	Use of virus, viral particle or viral elements as a vector	2710/24222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/24042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/24223	Virus like particles [VLP]
2710/24043	viral genome or elements thereof as genetic vector	2710/24231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/24044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/24232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/24045	Special targeting system for viral vectors	2710/24233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/24051	. . .	Methods of production or purification of viral material	2710/24234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/24052	relating to complementing cells and packaging systems for producing virus or viral particles	2710/24241	Use of virus, viral particle or viral elements as a vector
2710/24061	. . .	Methods of inactivation or attenuation	2710/24242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/24062	by genetic engineering	2710/24243	viral genome or elements thereof as genetic vector
2710/24063	by chemical treatment	2710/24244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/24064	by serial passage	2710/24245	Special targeting system for viral vectors
2710/24071	. . .	Demonstrated <u>in vivo</u> effect			
2710/24088	. . .	For redistribution			
2710/24111	. . .	Orthopoxvirus, e.g. vaccinia virus, variola			

2710/24251 Methods of production or purification of viral material	2720/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/24252 relating to complementing cells and packaging systems for producing virus or viral particles	2720/10041 Use of virus, viral particle or viral elements as a vector
2710/24261 Methods of inactivation or attenuation	2720/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/24262 by genetic engineering	2720/10043 viral genome or elements thereof as genetic vector
2710/24263 by chemical treatment	2720/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/24264 by serial passage	2720/10045 Special targeting system for viral vectors
2710/24271 Demonstrated <u>in vivo</u> effect	2720/10051 Methods of production or purification of viral material
2710/24288 For redistribution	2720/10052 relating to complementing cells and packaging systems for producing virus or viral particles
2720/00	dsRNA Viruses (not used)	2720/10061 Methods of inactivation or attenuation
2720/00011	. dsRNA Viruses	2720/10062 by genetic engineering
2720/00021	. . Viruses as such, e.g. new isolates, mutants or their genomic sequences	2720/10063 by chemical treatment
2720/00022	. . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2720/10064 by serial passage
2720/00023	. . Virus like particles [VLP]	2720/10071 Demonstrated <u>in vivo</u> effect
2720/00031	. . Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2720/10088 For redistribution
2720/00032	. . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2720/12011 Reoviridae
2720/00033	. . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2720/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/00034	. . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2720/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/00041	. . Use of virus, viral particle or viral elements as a vector	2720/12023 Virus like particles [VLP]
2720/00042	. . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2720/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/00043	. . . viral genome or elements thereof as genetic vector	2720/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/00044	. . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2720/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/00045	. . . Special targeting system for viral vectors	2720/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/00051	. . Methods of production or purification of viral material	2720/12041 Use of virus, viral particle or viral elements as a vector
2720/00052	. . . relating to complementing cells and packaging systems for producing virus or viral particles	2720/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/00061	. . Methods of inactivation or attenuation	2720/12043 viral genome or elements thereof as genetic vector
2720/00062	. . . by genetic engineering	2720/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/00063	. . . by chemical treatment	2720/12045 Special targeting system for viral vectors
2720/00064	. . . by serial passage	2720/12051 Methods of production or purification of viral material
2720/00071	. . Demonstrated <u>in vivo</u> effect	2720/12052 relating to complementing cells and packaging systems for producing virus or viral particles
2720/00088	. . For redistribution	2720/12061 Methods of inactivation or attenuation
2720/10011	. . Birnaviridae	2720/12062 by genetic engineering
2720/10021	. . . Viruses as such, e.g. new isolates, mutants or their genomic sequences	2720/12063 by chemical treatment
2720/10022	. . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2720/12064 by serial passage
2720/10023	. . . Virus like particles [VLP]	2720/12071 Demonstrated <u>in vivo</u> effect
2720/10031	. . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2720/12088 For redistribution
2720/10032	. . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2720/12111 Orbivirus, e.g. bluetongue virus
2720/10033	. . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory		

2720/12121	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2720/12251	Methods of production or purification of viral material
2720/12122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2720/12252	relating to complementing cells and packaging systems for producing virus or viral particles
2720/12123	Virus like particles [VLP]	2720/12261	Methods of inactivation or attenuation
2720/12131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2720/12262	by genetic engineering
2720/12132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2720/12263	by chemical treatment
2720/12133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2720/12264	by serial passage
2720/12134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2720/12271	Demonstrated <u>in vivo</u> effect
2720/12141	Use of virus, viral particle or viral elements as a vector	2720/12288	For redistribution
2720/12142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2720/12311	Rotavirus, e.g. rotavirus A
2720/12143	viral genome or elements thereof as genetic vector	2720/12321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2720/12322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12145	Special targeting system for viral vectors	2720/12323	Virus like particles [VLP]
2720/12151	Methods of production or purification of viral material	2720/12331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12152	relating to complementing cells and packaging systems for producing virus or viral particles	2720/12332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12161	Methods of inactivation or attenuation	2720/12333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12162	by genetic engineering	2720/12334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12163	by chemical treatment	2720/12341	Use of virus, viral particle or viral elements as a vector
2720/12164	by serial passage	2720/12342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12171	Demonstrated <u>in vivo</u> effect	2720/12343	viral genome or elements thereof as genetic vector
2720/12188	For redistribution	2720/12344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12211	Orthoreovirus, e.g. mammalian orthoreovirus	2720/12345	Special targeting system for viral vectors
2720/12221	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2720/12351	Methods of production or purification of viral material
2720/12222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2720/12352	relating to complementing cells and packaging systems for producing virus or viral particles
2720/12223	Virus like particles [VLP]	2720/12361	Methods of inactivation or attenuation
2720/12231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2720/12362	by genetic engineering
2720/12232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2720/12363	by chemical treatment
2720/12233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2720/12364	by serial passage
2720/12234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2720/12371	Demonstrated <u>in vivo</u> effect
2720/12241	Use of virus, viral particle or viral elements as a vector	2720/12388	For redistribution
2720/12242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2730/00		Reverse Transcribing DNA Viruses (not used)
2720/12243	viral genome or elements thereof as genetic vector	2730/00011	Reverse Transcribing DNA Viruses
2720/12244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2730/00021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12245	Special targeting system for viral vectors	2730/00022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
			2730/00023	Virus like particles [VLP]
			2730/00031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
			2730/00032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2730/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/00041 . . . Use of virus, viral particle or viral elements as a vector
- 2730/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/00043 viral genome or elements thereof as genetic vector
- 2730/00044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/00045 Special targeting system for viral vectors
- 2730/00051 . . . Methods of production or purification of viral material
- 2730/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/00061 . . . Methods of inactivation or attenuation
- 2730/00062 by genetic engineering
- 2730/00063 by chemical treatment
- 2730/00064 by serial passage
- 2730/00071 . . . Demonstrated in vivo effect
- 2730/00088 . . . For redistribution
- 2730/10011 . . . Hepadnaviridae
- 2730/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/10023 Virus like particles [VLP]
- 2730/10031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/10032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/10033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/10041 Use of virus, viral particle or viral elements as a vector
- 2730/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/10043 viral genome or elements thereof as genetic vector
- 2730/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/10045 Special targeting system for viral vectors
- 2730/10051 Methods of production or purification of viral material
- 2730/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/10061 Methods of inactivation or attenuation
- 2730/10062 by genetic engineering
- 2730/10063 by chemical treatment
- 2730/10064 by serial passage
- 2730/10071 Demonstrated in vivo effect
- 2730/10088 For redistribution
- 2730/10111 Orthohepadnavirus, e.g. hepatitis B virus
- 2730/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/10123 Virus like particles [VLP]
- 2730/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/10141 Use of virus, viral particle or viral elements as a vector
- 2730/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/10143 viral genome or elements thereof as genetic vector
- 2730/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/10145 Special targeting system for viral vectors
- 2730/10151 Methods of production or purification of viral material
- 2730/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/10161 Methods of inactivation or attenuation
- 2730/10162 by genetic engineering
- 2730/10163 by chemical treatment
- 2730/10164 by serial passage
- 2730/10171 Demonstrated in vivo effect
- 2730/10188 For redistribution
- 2740/00** **Reverse Transcribing RNA Viruses (not used)**
- 2740/00011 . . . Reverse Transcribing RNA Viruses
- 2740/00021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/00022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/00023 Virus like particles [VLP]
- 2740/00031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/00032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/00033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/00034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/00041 Use of virus, viral particle or viral elements as a vector
- 2740/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/00043 viral genome or elements thereof as genetic vector

2740/00044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/11033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/00045	. . .	Special targeting system for viral vectors	2740/11034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/00051	. . .	Methods of production or purification of viral material	2740/11041	Use of virus, viral particle or viral elements as a vector
2740/00052	. . .	relating to complementing cells and packaging systems for producing virus or viral particles	2740/11042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/00061	. . .	Methods of inactivation or attenuation	2740/11043	viral genome or elements thereof as genetic vector
2740/00062	. . .	by genetic engineering	2740/11044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/00063	. . .	by chemical treatment	2740/11045	Special targeting system for viral vectors
2740/00064	. . .	by serial passage	2740/11051	Methods of production or purification of viral material
2740/00071	. . .	Demonstrated <u>in vivo</u> effect	2740/11052	relating to complementing cells and packaging systems for producing virus or viral particles
2740/00088	. . .	For redistribution	2740/11061	Methods of inactivation or attenuation
2740/10011	. . .	Retroviridae	2740/11062	by genetic engineering
2740/10021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2740/11063	by chemical treatment
2740/10022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2740/11064	by serial passage
2740/10023	. . .	Virus like particles [VLP]	2740/11071	Demonstrated <u>in vivo</u> effect
2740/10031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2740/11088	For redistribution
2740/10032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/12011	. . .	Betaretrovirus, e.g. mouse mammary tumour virus
2740/10033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2740/12021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/10034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/12022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/10041	. . .	Use of virus, viral particle or viral elements as a vector	2740/12023	Virus like particles [VLP]
2740/10042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/12031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/10043	viral genome or elements thereof as genetic vector	2740/12032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/10044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/12033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/10045	Special targeting system for viral vectors	2740/12034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/10051	Methods of production or purification of viral material	2740/12041	Use of virus, viral particle or viral elements as a vector
2740/10052	relating to complementing cells and packaging systems for producing virus or viral particles	2740/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/10061	Methods of inactivation or attenuation	2740/12043	viral genome or elements thereof as genetic vector
2740/10062	by genetic engineering	2740/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/10063	by chemical treatment	2740/12045	Special targeting system for viral vectors
2740/10064	by serial passage	2740/12051	Methods of production or purification of viral material
2740/10071	Demonstrated <u>in vivo</u> effect	2740/12052	relating to complementing cells and packaging systems for producing virus or viral particles
2740/10088	For redistribution	2740/12061	Methods of inactivation or attenuation
2740/11011	Alpharetrovirus, e.g. avian leucosis virus	2740/12062	by genetic engineering
2740/11021	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2740/12063	by chemical treatment
2740/11022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2740/12064	by serial passage
2740/11023	Virus like particles [VLP]			
2740/11031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			
2740/11032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent			

2740/12071	Demonstrated <u>in vivo</u> effect	2740/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/12088	For redistribution	2740/14045	Special targeting system for viral vectors
2740/13011	Gammaretrovirus, e.g. murine leukaemia virus	2740/14051	Methods of production or purification of viral material
2740/13021	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2740/14052	relating to complementing cells and packaging systems for producing virus or viral particles
2740/13022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2740/14061	Methods of inactivation or attenuation
2740/13023	Virus like particles [VLP]	2740/14062	by genetic engineering
2740/13031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2740/14063	by chemical treatment
2740/13032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/14064	by serial passage
2740/13033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2740/14071	Demonstrated <u>in vivo</u> effect
2740/13034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/14088	For redistribution
2740/13041	Use of virus, viral particle or viral elements as a vector	2740/15011	Lentivirus, not HIV, e.g. FIV, SIV
2740/13042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/15021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/13043	viral genome or elements thereof as genetic vector	2740/15022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/13044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/15023	Virus like particles [VLP]
2740/13045	Special targeting system for viral vectors	2740/15031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/13051	Methods of production or purification of viral material	2740/15032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/13052	relating to complementing cells and packaging systems for producing virus or viral particles	2740/15033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/13061	Methods of inactivation or attenuation	2740/15034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/13062	by genetic engineering	2740/15041	Use of virus, viral particle or viral elements as a vector
2740/13063	by chemical treatment	2740/15042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/13064	by serial passage	2740/15043	viral genome or elements thereof as genetic vector
2740/13071	Demonstrated <u>in vivo</u> effect	2740/15044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/13088	For redistribution	2740/15045	Special targeting system for viral vectors
2740/14011	Deltaretrovirus, e.g. bovine leukaemia virus	2740/15051	Methods of production or purification of viral material
2740/14021	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2740/15052	relating to complementing cells and packaging systems for producing virus or viral particles
2740/14022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2740/15061	Methods of inactivation or attenuation
2740/14023	Virus like particles [VLP]	2740/15062	by genetic engineering
2740/14031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2740/15063	by chemical treatment
2740/14032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/15064	by serial passage
2740/14033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2740/15071	Demonstrated <u>in vivo</u> effect
2740/14034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/15088	For redistribution
2740/14041	Use of virus, viral particle or viral elements as a vector	2740/16011	Human Immunodeficiency Virus, HIV
2740/14042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/16021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/14043	viral genome or elements thereof as genetic vector	2740/16022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
			2740/16023	Virus like particles [VLP]
			2740/16031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
			2740/16032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2740/16033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/16034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16041	Use of virus, viral particle or viral elements as a vector
2740/16042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/16043	viral genome or elements thereof as genetic vector
2740/16044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/16045	Special targeting system for viral vectors
2740/16051	Methods of production or purification of viral material
2740/16052	relating to complementing cells and packaging systems for producing virus or viral particles
2740/16061	Methods of inactivation or attenuation
2740/16062	by genetic engineering
2740/16063	by chemical treatment
2740/16064	by serial passage
2740/16071	Demonstrated <u>in vivo</u> effect
2740/16088	For redistribution
2740/16111	concerning HIV env
2740/16122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16171	Demonstrated <u>in vivo</u> effect
2740/16188	For redistribution
2740/16211	concerning HIV gagpol
2740/16222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16271	Demonstrated <u>in vivo</u> effect
2740/16288	For redistribution
2740/16311	concerning HIV regulatory proteins
2740/16322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16371	Demonstrated <u>in vivo</u> effect
2740/16388	For redistribution
2740/17011	Spumavirus, e.g. chimpanzee foamy virus
2740/17021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/17022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/17023	Virus like particles [VLP]
2740/17031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/17032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/17033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/17034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/17041	Use of virus, viral particle or viral elements as a vector
2740/17042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/17043	viral genome or elements thereof as genetic vector
2740/17044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/17045	Special targeting system for viral vectors
2740/17051	Methods of production or purification of viral material
2740/17052	relating to complementing cells and packaging systems for producing virus or viral particles
2740/17061	Methods of inactivation or attenuation
2740/17062	by genetic engineering
2740/17063	by chemical treatment
2740/17064	by serial passage
2740/17071	Demonstrated <u>in vivo</u> effect
2740/17088	For redistribution
2750/00		ssDNA Viruses (not used)
2750/00011	ssDNA Viruses
2750/00021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/00022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/00023	Virus like particles [VLP]
2750/00031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/00032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/00033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/00034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/00041	Use of virus, viral particle or viral elements as a vector
2750/00042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/00043	viral genome or elements thereof as genetic vector
2750/00044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/00045	Special targeting system for viral vectors
2750/00051	Methods of production or purification of viral material
2750/00052	relating to complementing cells and packaging systems for producing virus or viral particles
2750/00061	Methods of inactivation or attenuation
2750/00062	by genetic engineering

- 2750/00063 . . . by chemical treatment
- 2750/00064 . . . by serial passage
- 2750/00071 . . Demonstrated in vivo effect
- 2750/00088 . . For redistribution
- 2750/10011 . . Circoviridae
- 2750/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/10023 . . . Virus like particles [VLP]
- 2750/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/10043 viral genome or elements thereof as genetic vector
- 2750/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/10045 Special targeting system for viral vectors
- 2750/10051 . . . Methods of production or purification of viral material
- 2750/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/10061 . . . Methods of inactivation or attenuation
- 2750/10062 by genetic engineering
- 2750/10063 by chemical treatment
- 2750/10064 by serial passage
- 2750/10071 . . . Demonstrated in vivo effect
- 2750/10088 . . . For redistribution
- 2750/12011 . . Geminiviridae
- 2750/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/12023 . . . Virus like particles [VLP]
- 2750/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/12043 viral genome or elements thereof as genetic vector
- 2750/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/12045 Special targeting system for viral vectors
- 2750/12051 . . . Methods of production or purification of viral material
- 2750/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/12061 . . . Methods of inactivation or attenuation
- 2750/12062 by genetic engineering
- 2750/12063 by chemical treatment
- 2750/12064 by serial passage
- 2750/12071 . . . Demonstrated in vivo effect
- 2750/12088 . . . For redistribution
- 2750/14011 . . Parvoviridae
- 2750/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14023 . . . Virus like particles [VLP]
- 2750/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14043 viral genome or elements thereof as genetic vector
- 2750/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14045 Special targeting system for viral vectors
- 2750/14051 . . . Methods of production or purification of viral material
- 2750/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14061 . . . Methods of inactivation or attenuation
- 2750/14062 by genetic engineering
- 2750/14063 by chemical treatment
- 2750/14064 by serial passage
- 2750/14071 . . . Demonstrated in vivo effect
- 2750/14088 . . . For redistribution
- 2750/14111 . . . Dependovirus, e.g. adenoassociated viruses
- 2750/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14123 Virus like particles [VLP]
- 2750/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2750/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14141 Use of virus, viral particle or viral elements as a vector
- 2750/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14143 viral genome or elements thereof as genetic vector
- 2750/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14145 Special targeting system for viral vectors
- 2750/14151 Methods of production or purification of viral material
- 2750/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14161 Methods of inactivation or attenuation
- 2750/14162 by genetic engineering
- 2750/14163 by chemical treatment
- 2750/14164 by serial passage
- 2750/14171 Demonstrated in vivo effect
- 2750/14188 For redistribution
- 2750/14211 . . . Erythrovirus, e.g. B19 virus
- 2750/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14223 Virus like particles [VLP]
- 2750/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14241 Use of virus, viral particle or viral elements as a vector
- 2750/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14243 viral genome or elements thereof as genetic vector
- 2750/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14245 Special targeting system for viral vectors
- 2750/14251 Methods of production or purification of viral material
- 2750/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14261 Methods of inactivation or attenuation
- 2750/14262 by genetic engineering
- 2750/14263 by chemical treatment
- 2750/14264 by serial passage
- 2750/14271 Demonstrated in vivo effect
- 2750/14288 For redistribution
- 2750/14311 . . . Parvovirus, e.g. minute virus of mice
- 2750/14321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14323 Virus like particles [VLP]
- 2750/14331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14341 Use of virus, viral particle or viral elements as a vector
- 2750/14342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14343 viral genome or elements thereof as genetic vector
- 2750/14344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14345 Special targeting system for viral vectors
- 2750/14351 Methods of production or purification of viral material
- 2750/14352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14361 Methods of inactivation or attenuation
- 2750/14362 by genetic engineering
- 2750/14363 by chemical treatment
- 2750/14364 by serial passage
- 2750/14371 Demonstrated in vivo effect
- 2750/14388 For redistribution
- 2760/00** **ssRNA Viruses negative-sense** (not used)
- 2760/00011 . ssRNA Viruses negative-sense
- 2760/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/00023 . . Virus like particles [VLP]
- 2760/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/00041 . . Use of virus, viral particle or viral elements as a vector
- 2760/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule

2760/00043	. . .	viral genome or elements thereof as genetic vector	2760/10132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/00044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/10133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/00045	. . .	Special targeting system for viral vectors	2760/10134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/00051	. .	Methods of production or purification of viral material	2760/10141	Use of virus, viral particle or viral elements as a vector
2760/00052	. . .	relating to complementing cells and packaging systems for producing virus or viral particles	2760/10142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/00061	. .	Methods of inactivation or attenuation	2760/10143	viral genome or elements thereof as genetic vector
2760/00062	. . .	by genetic engineering	2760/10144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/00063	. . .	by chemical treatment	2760/10145	Special targeting system for viral vectors
2760/00064	. . .	by serial passage	2760/10151	Methods of production or purification of viral material
2760/00071	. .	Demonstrated <u>in vivo</u> effect	2760/10152	relating to complementing cells and packaging systems for producing virus or viral particles
2760/00088	. .	For redistribution	2760/10161	Methods of inactivation or attenuation
2760/10011	. .	Arenaviridae	2760/10162	by genetic engineering
2760/10021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/10163	by chemical treatment
2760/10022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/10164	by serial passage
2760/10023	. . .	Virus like particles [VLP]	2760/10171	Demonstrated <u>in vivo</u> effect
2760/10031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/10188	For redistribution
2760/10032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/12011	. .	Bunyaviridae
2760/10033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/10034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/10041	. . .	Use of virus, viral particle or viral elements as a vector	2760/12023	. . .	Virus like particles [VLP]
2760/10042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/10043	viral genome or elements thereof as genetic vector	2760/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/10044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/10045	Special targeting system for viral vectors	2760/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/10051	. . .	Methods of production or purification of viral material	2760/12041	. . .	Use of virus, viral particle or viral elements as a vector
2760/10052	relating to complementing cells and packaging systems for producing virus or viral particles	2760/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/10061	. . .	Methods of inactivation or attenuation	2760/12043	viral genome or elements thereof as genetic vector
2760/10062	by genetic engineering	2760/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/10063	by chemical treatment	2760/12045	Special targeting system for viral vectors
2760/10064	by serial passage	2760/12051	. . .	Methods of production or purification of viral material
2760/10071	. . .	Demonstrated <u>in vivo</u> effect	2760/12052	relating to complementing cells and packaging systems for producing virus or viral particles
2760/10088	. . .	For redistribution	2760/12061	. . .	Methods of inactivation or attenuation
2760/10111	. . .	Deltavirus, e.g. hepatitis delta virus	2760/12062	by genetic engineering
2760/10121	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/12063	by chemical treatment
2760/10122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2760/10123	Virus like particles [VLP]			
2760/10131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			

- 2760/12064 by serial passage
- 2760/12071 . . . Demonstrated in vivo effect
- 2760/12088 . . . For redistribution
- 2760/12111 . . . Hantavirus, e.g. Hantaan virus
- 2760/12121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12123 Virus like particles [VLP]
- 2760/12131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12141 Use of virus, viral particle or viral elements as a vector
- 2760/12142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12143 viral genome or elements thereof as genetic vector
- 2760/12144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12145 Special targeting system for viral vectors
- 2760/12151 Methods of production or purification of viral material
- 2760/12152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12161 Methods of inactivation or attenuation
- 2760/12162 by genetic engineering
- 2760/12163 by chemical treatment
- 2760/12164 by serial passage
- 2760/12171 Demonstrated in vivo effect
- 2760/12188 For redistribution
- 2760/12211 . . . Phlebovirus, e.g. Rift Valley fever virus
- 2760/12221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12223 Virus like particles [VLP]
- 2760/12231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12241 Use of virus, viral particle or viral elements as a vector
- 2760/12242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12243 viral genome or elements thereof as genetic vector
- 2760/12244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12245 Special targeting system for viral vectors
- 2760/12251 Methods of production or purification of viral material
- 2760/12252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12261 Methods of inactivation or attenuation
- 2760/12262 by genetic engineering
- 2760/12263 by chemical treatment
- 2760/12264 by serial passage
- 2760/12271 Demonstrated in vivo effect
- 2760/12288 For redistribution
- 2760/14011 . . . Filoviridae
- 2760/14021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14023 Virus like particles [VLP]
- 2760/14031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14041 Use of virus, viral particle or viral elements as a vector
- 2760/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14043 viral genome or elements thereof as genetic vector
- 2760/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14045 Special targeting system for viral vectors
- 2760/14051 Methods of production or purification of viral material
- 2760/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14061 Methods of inactivation or attenuation
- 2760/14062 by genetic engineering
- 2760/14063 by chemical treatment
- 2760/14064 by serial passage
- 2760/14071 Demonstrated in vivo effect
- 2760/14088 For redistribution
- 2760/14111 Ebolavirus, e.g. Zaire ebolavirus
- 2760/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14123 Virus like particles [VLP]
- 2760/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2760/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14141 Use of virus, viral particle or viral elements as a vector
- 2760/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14143 viral genome or elements thereof as genetic vector
- 2760/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14145 Special targeting system for viral vectors
- 2760/14151 Methods of production or purification of viral material
- 2760/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14161 Methods of inactivation or attenuation
- 2760/14162 by genetic engineering
- 2760/14163 by chemical treatment
- 2760/14164 by serial passage
- 2760/14171 Demonstrated in vivo effect
- 2760/14188 For redistribution
- 2760/14211 . . . Marburgvirus, e.g. lake Victoria marburgvirus
- 2760/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14223 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14241 Use of virus, viral particle or viral elements as a vector
- 2760/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14243 viral genome or elements thereof as genetic vector
- 2760/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14245 Special targeting system for viral vectors
- 2760/14251 Methods of production or purification of viral material
- 2760/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14261 Methods of inactivation or attenuation
- 2760/14262 by genetic engineering
- 2760/14263 by chemical treatment
- 2760/14264 by serial passage
- 2760/14271 Demonstrated in vivo effect
- 2760/14288 For redistribution
- 2760/16011 . . . Orthomyxoviridae
- 2760/16021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16023 Virus like particles [VLP]
- 2760/16031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16041 Use of virus, viral particle or viral elements as a vector
- 2760/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16043 viral genome or elements thereof as genetic vector
- 2760/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16045 Special targeting system for viral vectors
- 2760/16051 Methods of production or purification of viral material
- 2760/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16061 Methods of inactivation or attenuation
- 2760/16062 by genetic engineering
- 2760/16063 by chemical treatment
- 2760/16064 by serial passage
- 2760/16071 Demonstrated in vivo effect
- 2760/16088 For redistribution
- 2760/16111 Influenzavirus A, i.e. influenza A virus
- 2760/16121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16123 Virus like particles [VLP]
- 2760/16131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16141 Use of virus, viral particle or viral elements as a vector
- 2760/16142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16143 viral genome or elements thereof as genetic vector

2760/16144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/16333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/16145	Special targeting system for viral vectors	2760/16334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/16151	Methods of production or purification of viral material	2760/16341	Use of virus, viral particle or viral elements as a vector
2760/16152	relating to complementing cells and packaging systems for producing virus or viral particles	2760/16342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/16161	Methods of inactivation or attenuation	2760/16343	viral genome or elements thereof as genetic vector
2760/16162	by genetic engineering	2760/16344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/16163	by chemical treatment	2760/16345	Special targeting system for viral vectors
2760/16164	by serial passage	2760/16351	Methods of production or purification of viral material
2760/16171	Demonstrated <u>in vivo</u> effect	2760/16352	relating to complementing cells and packaging systems for producing virus or viral particles
2760/16188	For redistribution	2760/16361	Methods of inactivation or attenuation
2760/16211	Influenzavirus B, i.e. influenza B virus	2760/16362	by genetic engineering
2760/16221	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/16363	by chemical treatment
2760/16222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/16364	by serial passage
2760/16223	Virus like particles [VLP]	2760/16371	Demonstrated <u>in vivo</u> effect
2760/16231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/16388	For redistribution
2760/16232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/18011	Paramyxoviridae
2760/16233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/18021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/16234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/18022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/16241	Use of virus, viral particle or viral elements as a vector	2760/18023	Virus like particles [VLP]
2760/16242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/18031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/16243	viral genome or elements thereof as genetic vector	2760/18032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/16244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/18033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/16245	Special targeting system for viral vectors	2760/18034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/16251	Methods of production or purification of viral material	2760/18041	Use of virus, viral particle or viral elements as a vector
2760/16252	relating to complementing cells and packaging systems for producing virus or viral particles	2760/18042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/16261	Methods of inactivation or attenuation	2760/18043	viral genome or elements thereof as genetic vector
2760/16262	by genetic engineering	2760/18044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/16263	by chemical treatment	2760/18045	Special targeting system for viral vectors
2760/16264	by serial passage	2760/18051	Methods of production or purification of viral material
2760/16271	Demonstrated <u>in vivo</u> effect	2760/18052	relating to complementing cells and packaging systems for producing virus or viral particles
2760/16288	For redistribution	2760/18061	Methods of inactivation or attenuation
2760/16311	Influenzavirus C, i.e. influenza C virus	2760/18062	by genetic engineering
2760/16321	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/18063	by chemical treatment
2760/16322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/18064	by serial passage
2760/16323	Virus like particles [VLP]	2760/18071	Demonstrated <u>in vivo</u> effect
2760/16331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			
2760/16332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent			

2760/18088	. . .	For redistribution	2760/18244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18111	. . .	Avulavirus, e.g. Newcastle disease virus	2760/18245	Special targeting system for viral vectors
2760/18121	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/18251	Methods of production or purification of viral material
2760/18122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/18252	relating to complementing cells and packaging systems for producing virus or viral particles
2760/18123	Virus like particles [VLP]	2760/18261	Methods of inactivation or attenuation
2760/18131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/18262	by genetic engineering
2760/18132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/18263	by chemical treatment
2760/18133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/18264	by serial passage
2760/18134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/18271	Demonstrated <u>in vivo</u> effect
2760/18141	Use of virus, viral particle or viral elements as a vector	2760/18288	For redistribution
2760/18142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/18311	. . .	Metapneumovirus, e.g. avian pneumovirus
2760/18143	viral genome or elements thereof as genetic vector	2760/18321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/18144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/18322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/18145	Special targeting system for viral vectors	2760/18323	Virus like particles [VLP]
2760/18151	Methods of production or purification of viral material	2760/18331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/18152	relating to complementing cells and packaging systems for producing virus or viral particles	2760/18332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/18161	Methods of inactivation or attenuation	2760/18333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18162	by genetic engineering	2760/18334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18163	by chemical treatment	2760/18341	Use of virus, viral particle or viral elements as a vector
2760/18164	by serial passage	2760/18342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18171	Demonstrated <u>in vivo</u> effect	2760/18343	viral genome or elements thereof as genetic vector
2760/18188	For redistribution	2760/18344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18211	. . .	Henipavirus, e.g. hendra virus	2760/18345	Special targeting system for viral vectors
2760/18221	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/18351	Methods of production or purification of viral material
2760/18222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/18352	relating to complementing cells and packaging systems for producing virus or viral particles
2760/18223	Virus like particles [VLP]	2760/18361	Methods of inactivation or attenuation
2760/18231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/18362	by genetic engineering
2760/18232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/18363	by chemical treatment
2760/18233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/18364	by serial passage
2760/18234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/18371	Demonstrated <u>in vivo</u> effect
2760/18241	Use of virus, viral particle or viral elements as a vector	2760/18388	For redistribution
2760/18242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/18411	. . .	Morbillivirus, e.g. Measles virus, canine distemper
2760/18243	viral genome or elements thereof as genetic vector	2760/18421	Viruses as such, e.g. new isolates, mutants or their genomic sequences
			2760/18422	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
			2760/18423	Virus like particles [VLP]
			2760/18431	Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2760/18432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18441 Use of virus, viral particle or viral elements as a vector
- 2760/18442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18443 viral genome or elements thereof as genetic vector
- 2760/18444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18445 Special targeting system for viral vectors
- 2760/18451 Methods of production or purification of viral material
- 2760/18452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18461 Methods of inactivation or attenuation
- 2760/18462 by genetic engineering
- 2760/18463 by chemical treatment
- 2760/18464 by serial passage
- 2760/18471 Demonstrated in vivo effect
- 2760/18488 For redistribution
- 2760/18511 Pneumovirus, e.g. human respiratory syncytial virus
- 2760/18521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18523 Virus like particles [VLP]
- 2760/18531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18541 Use of virus, viral particle or viral elements as a vector
- 2760/18542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18543 viral genome or elements thereof as genetic vector
- 2760/18544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18545 Special targeting system for viral vectors
- 2760/18551 Methods of production or purification of viral material
- 2760/18552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18561 Methods of inactivation or attenuation
- 2760/18562 by genetic engineering
- 2760/18563 by chemical treatment
- 2760/18564 by serial passage
- 2760/18571 Demonstrated in vivo effect
- 2760/18588 For redistribution
- 2760/18611 Respirovirus, e.g. Bovine, human parainfluenza 1,3
- 2760/18621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18623 Virus like particles [VLP]
- 2760/18631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18641 Use of virus, viral particle or viral elements as a vector
- 2760/18642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18643 viral genome or elements thereof as genetic vector
- 2760/18644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18645 Special targeting system for viral vectors
- 2760/18651 Methods of production or purification of viral material
- 2760/18652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18661 Methods of inactivation or attenuation
- 2760/18662 by genetic engineering
- 2760/18663 by chemical treatment
- 2760/18664 by serial passage
- 2760/18671 Demonstrated in vivo effect
- 2760/18688 For redistribution
- 2760/18711 Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- 2760/18721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18723 Virus like particles [VLP]
- 2760/18731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18741 Use of virus, viral particle or viral elements as a vector

2760/18742	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/20032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/18743	viral genome or elements thereof as genetic vector	2760/20033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18744	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/20034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18745	Special targeting system for viral vectors	2760/20041	. . .	Use of virus, viral particle or viral elements as a vector
2760/18751	Methods of production or purification of viral material	2760/20042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18752	relating to complementing cells and packaging systems for producing virus or viral particles	2760/20043	viral genome or elements thereof as genetic vector
2760/18761	Methods of inactivation or attenuation	2760/20044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18762	by genetic engineering	2760/20045	Special targeting system for viral vectors
2760/18763	by chemical treatment	2760/20051	. . .	Methods of production or purification of viral material
2760/18764	by serial passage	2760/20052	relating to complementing cells and packaging systems for producing virus or viral particles
2760/18771	Demonstrated <u>in vivo</u> effect	2760/20061	. . .	Methods of inactivation or attenuation
2760/18788	For redistribution	2760/20062	by genetic engineering
2760/18811	. . .	Sendai virus	2760/20063	by chemical treatment
2760/18821	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/20064	by serial passage
2760/18822	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/20071	. . .	Demonstrated <u>in vivo</u> effect
2760/18823	Virus like particles [VLP]	2760/20088	. . .	For redistribution
2760/18831	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/20111	. . .	Lyssavirus, e.g. rabies virus
2760/18832	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/20121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/18833	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/20122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/18834	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/20123	Virus like particles [VLP]
2760/18841	Use of virus, viral particle or viral elements as a vector	2760/20131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/18842	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/20132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/18843	viral genome or elements thereof as genetic vector	2760/20133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18845	Special targeting system for viral vectors	2760/20134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18851	Methods of production or purification of viral material	2760/20141	Use of virus, viral particle or viral elements as a vector
2760/18852	relating to complementing cells and packaging systems for producing virus or viral particles	2760/20142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18861	Methods of inactivation or attenuation	2760/20143	viral genome or elements thereof as genetic vector
2760/18862	by genetic engineering	2760/20144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18863	by chemical treatment	2760/20145	Special targeting system for viral vectors
2760/18864	by serial passage	2760/20151	Methods of production or purification of viral material
2760/18871	Demonstrated <u>in vivo</u> effect	2760/20152	relating to complementing cells and packaging systems for producing virus or viral particles
2760/18888	For redistribution	2760/20161	Methods of inactivation or attenuation
2760/20011	. .	Rhabdoviridae	2760/20162	by genetic engineering
2760/20021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/20163	by chemical treatment
2760/20022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2760/20023	. . .	Virus like particles [VLP]			
2760/20031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			

- 2760/20164 by serial passage
- 2760/20171 Demonstrated in vivo effect
- 2760/20188 For redistribution
- 2760/20211 . . . Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- 2760/20221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20223 Virus like particles [VLP]
- 2760/20231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/20234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/20241 Use of virus, viral particle or viral elements as a vector
- 2760/20242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/20243 viral genome or elements thereof as genetic vector
- 2760/20244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/20245 Special targeting system for viral vectors
- 2760/20251 Methods of production or purification of viral material
- 2760/20252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/20261 Methods of inactivation or attenuation
- 2760/20262 by genetic engineering
- 2760/20263 by chemical treatment
- 2760/20264 by serial passage
- 2760/20271 Demonstrated in vivo effect
- 2760/20288 For redistribution
- 2770/00** **ssRNA Viruses positive-sense (not used)**
- 2770/00011 . ssRNA Viruses positive-sense
- 2770/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/00023 . . Virus like particles [VLP]
- 2770/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/00041 . . Use of virus, viral particle or viral elements as a vector
- 2770/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/00043 . . . viral genome or elements thereof as genetic vector
- 2770/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/00045 . . . Special targeting system for viral vectors
- 2770/00051 . . . Methods of production or purification of viral material
- 2770/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/00061 . . . Methods of inactivation or attenuation
- 2770/00062 by genetic engineering
- 2770/00063 by chemical treatment
- 2770/00064 by serial passage
- 2770/00071 . . . Demonstrated in vivo effect
- 2770/00088 . . . For redistribution
- 2770/10011 . . Arteriviridae
- 2770/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/10023 . . . Virus like particles [VLP]
- 2770/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/10043 viral genome or elements thereof as genetic vector
- 2770/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/10045 Special targeting system for viral vectors
- 2770/10051 . . . Methods of production or purification of viral material
- 2770/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/10061 . . . Methods of inactivation or attenuation
- 2770/10062 by genetic engineering
- 2770/10063 by chemical treatment
- 2770/10064 by serial passage
- 2770/10071 . . . Demonstrated in vivo effect
- 2770/10088 . . . For redistribution
- 2770/12011 . . Astroviridae
- 2770/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/12023 . . . Virus like particles [VLP]

- 2770/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/12043 viral genome or elements thereof as genetic vector
- 2770/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/12045 Special targeting system for viral vectors
- 2770/12051 . . . Methods of production or purification of viral material
- 2770/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/12061 . . . Methods of inactivation or attenuation
- 2770/12062 by genetic engineering
- 2770/12063 by chemical treatment
- 2770/12064 by serial passage
- 2770/12071 . . . Demonstrated in vivo effect
- 2770/12088 . . . For redistribution
- 2770/14011 . . Bromoviridae
- 2770/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/14023 . . . Virus like particles [VLP]
- 2770/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/14043 viral genome or elements thereof as genetic vector
- 2770/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/14045 Special targeting system for viral vectors
- 2770/14051 . . . Methods of production or purification of viral material
- 2770/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/14061 . . . Methods of inactivation or attenuation
- 2770/14062 by genetic engineering
- 2770/14063 by chemical treatment
- 2770/14064 by serial passage
- 2770/14071 . . . Demonstrated in vivo effect
- 2770/14088 . . . For redistribution
- 2770/16011 . . Caliciviridae
- 2770/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/16023 . . . Virus like particles [VLP]
- 2770/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/16043 viral genome or elements thereof as genetic vector
- 2770/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/16045 Special targeting system for viral vectors
- 2770/16051 . . . Methods of production or purification of viral material
- 2770/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/16061 . . . Methods of inactivation or attenuation
- 2770/16062 by genetic engineering
- 2770/16063 by chemical treatment
- 2770/16064 by serial passage
- 2770/16071 . . . Demonstrated in vivo effect
- 2770/16088 . . . For redistribution
- 2770/18011 . . Comoviridae
- 2770/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/18023 . . . Virus like particles [VLP]
- 2770/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule

- 2770/18043 viral genome or elements thereof as genetic vector
- 2770/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/18045 Special targeting system for viral vectors
- 2770/18051 Methods of production or purification of viral material
- 2770/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/18061 Methods of inactivation or attenuation
- 2770/18062 by genetic engineering
- 2770/18063 by chemical treatment
- 2770/18064 by serial passage
- 2770/18071 Demonstrated in vivo effect
- 2770/18088 For redistribution
- 2770/20011 Coronaviridae
- 2770/20021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/20023 Virus like particles [VLP]
- 2770/20031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/20032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/20033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/20034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/20041 Use of virus, viral particle or viral elements as a vector
- 2770/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/20043 viral genome or elements thereof as genetic vector
- 2770/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/20045 Special targeting system for viral vectors
- 2770/20051 Methods of production or purification of viral material
- 2770/20052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/20061 Methods of inactivation or attenuation
- 2770/20062 by genetic engineering
- 2770/20063 by chemical treatment
- 2770/20064 by serial passage
- 2770/20071 Demonstrated in vivo effect
- 2770/20088 For redistribution
- 2770/22011 Dicistroviridae
- 2770/22021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/22022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/22023 Virus like particles [VLP]
- 2770/22031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/22032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/22033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/22034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/22041 Use of virus, viral particle or viral elements as a vector
- 2770/22042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/22043 viral genome or elements thereof as genetic vector
- 2770/22044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/22045 Special targeting system for viral vectors
- 2770/22051 Methods of production or purification of viral material
- 2770/22052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/22061 Methods of inactivation or attenuation
- 2770/22062 by genetic engineering
- 2770/22063 by chemical treatment
- 2770/22064 by serial passage
- 2770/22071 Demonstrated in vivo effect
- 2770/22088 For redistribution
- 2770/24011 Flaviviridae
- 2770/24021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24023 Virus like particles [VLP]
- 2770/24031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24041 Use of virus, viral particle or viral elements as a vector
- 2770/24042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24043 viral genome or elements thereof as genetic vector
- 2770/24044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24045 Special targeting system for viral vectors
- 2770/24051 Methods of production or purification of viral material
- 2770/24052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24061 Methods of inactivation or attenuation
- 2770/24062 by genetic engineering
- 2770/24063 by chemical treatment

- 2770/24064 by serial passage
- 2770/24071 . . . Demonstrated in vivo effect
- 2770/24088 . . . For redistribution
- 2770/24111 . . . Flavivirus, e.g. yellow fever virus, dengue, JEV
- 2770/24121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24123 Virus like particles [VLP]
- 2770/24131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24141 Use of virus, viral particle or viral elements as a vector
- 2770/24142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24143 viral genome or elements thereof as genetic vector
- 2770/24144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24145 Special targeting system for viral vectors
- 2770/24151 Methods of production or purification of viral material
- 2770/24152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24161 Methods of inactivation or attenuation
- 2770/24162 by genetic engineering
- 2770/24163 by chemical treatment
- 2770/24164 by serial passage
- 2770/24171 Demonstrated in vivo effect
- 2770/24188 For redistribution
- 2770/24211 . . . Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- 2770/24221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24223 Virus like particles [VLP]
- 2770/24231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24241 Use of virus, viral particle or viral elements as a vector
- 2770/24242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24243 viral genome or elements thereof as genetic vector
- 2770/24244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24245 Special targeting system for viral vectors
- 2770/24251 Methods of production or purification of viral material
- 2770/24252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24261 Methods of inactivation or attenuation
- 2770/24262 by genetic engineering
- 2770/24263 by chemical treatment
- 2770/24264 by serial passage
- 2770/24271 Demonstrated in vivo effect
- 2770/24288 For redistribution
- 2770/24311 . . . Pestivirus, e.g. bovine viral diarrhea virus
- 2770/24321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24323 Virus like particles [VLP]
- 2770/24331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24341 Use of virus, viral particle or viral elements as a vector
- 2770/24342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24343 viral genome or elements thereof as genetic vector
- 2770/24344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24345 Special targeting system for viral vectors
- 2770/24351 Methods of production or purification of viral material
- 2770/24352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24361 Methods of inactivation or attenuation
- 2770/24362 by genetic engineering
- 2770/24363 by chemical treatment
- 2770/24364 by serial passage
- 2770/24371 Demonstrated in vivo effect
- 2770/24388 For redistribution
- 2770/26011 . . Flexiviridae
- 2770/26021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/26022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/26023 . . . Virus like particles [VLP]
- 2770/26031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2770/26032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/26033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/26034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/26041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/26042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/26043 viral genome or elements thereof as genetic vector
- 2770/26044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/26045 Special targeting system for viral vectors
- 2770/26051 . . . Methods of production or purification of viral material
- 2770/26052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/26061 . . . Methods of inactivation or attenuation
- 2770/26062 by genetic engineering
- 2770/26063 by chemical treatment
- 2770/26064 by serial passage
- 2770/26071 . . . Demonstrated in vivo effect
- 2770/26088 . . . For redistribution
- 2770/28011 . . Hepeviridae
- 2770/28021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28023 . . . Virus like particles [VLP]
- 2770/28031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/28042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28043 viral genome or elements thereof as genetic vector
- 2770/28044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28045 Special targeting system for viral vectors
- 2770/28051 . . . Methods of production or purification of viral material
- 2770/28052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28061 . . . Methods of inactivation or attenuation
- 2770/28062 by genetic engineering
- 2770/28063 by chemical treatment
- 2770/28064 by serial passage
- 2770/28071 . . . Demonstrated in vivo effect
- 2770/28088 . . . For redistribution
- 2770/28111 . . . Hepevirus, e.g. hepatitis E virus
- 2770/28121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28123 Virus like particles [VLP]
- 2770/28131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28141 Use of virus, viral particle or viral elements as a vector
- 2770/28142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28143 viral genome or elements thereof as genetic vector
- 2770/28144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28145 Special targeting system for viral vectors
- 2770/28151 Methods of production or purification of viral material
- 2770/28152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28161 Methods of inactivation or attenuation
- 2770/28162 by genetic engineering
- 2770/28163 by chemical treatment
- 2770/28164 by serial passage
- 2770/28171 Demonstrated in vivo effect
- 2770/28188 For redistribution
- 2770/30011 . . Nodaviridae
- 2770/30021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/30022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/30023 . . . Virus like particles [VLP]
- 2770/30031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/30032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/30033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/30034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/30041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/30042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/30043 viral genome or elements thereof as genetic vector

- 2770/30044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/30045 Special targeting system for viral vectors
- 2770/30051 Methods of production or purification of viral material
- 2770/30052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/30061 Methods of inactivation or attenuation
- 2770/30062 by genetic engineering
- 2770/30063 by chemical treatment
- 2770/30064 by serial passage
- 2770/30071 Demonstrated in vivo effect
- 2770/30088 For redistribution
- 2770/32011 Picornaviridae
- 2770/32021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32023 Virus like particles [VLP]
- 2770/32031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32041 Use of virus, viral particle or viral elements as a vector
- 2770/32042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32043 viral genome or elements thereof as genetic vector
- 2770/32044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32045 Special targeting system for viral vectors
- 2770/32051 Methods of production or purification of viral material
- 2770/32052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32061 Methods of inactivation or attenuation
- 2770/32062 by genetic engineering
- 2770/32063 by chemical treatment
- 2770/32064 by serial passage
- 2770/32071 Demonstrated in vivo effect
- 2770/32088 For redistribution
- 2770/32111 Aphthovirus, e.g. footandmouth disease virus
- 2770/32121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32123 Virus like particles [VLP]
- 2770/32131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32141 Use of virus, viral particle or viral elements as a vector
- 2770/32142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32143 viral genome or elements thereof as genetic vector
- 2770/32144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32145 Special targeting system for viral vectors
- 2770/32151 Methods of production or purification of viral material
- 2770/32152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32161 Methods of inactivation or attenuation
- 2770/32162 by genetic engineering
- 2770/32163 by chemical treatment
- 2770/32164 by serial passage
- 2770/32171 Demonstrated in vivo effect
- 2770/32188 For redistribution
- 2770/32211 Cardiovirus, e.g. encephalomyocarditis virus
- 2770/32221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32223 Virus like particles [VLP]
- 2770/32231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32241 Use of virus, viral particle or viral elements as a vector
- 2770/32242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32243 viral genome or elements thereof as genetic vector
- 2770/32244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32245 Special targeting system for viral vectors
- 2770/32251 Methods of production or purification of viral material
- 2770/32252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32261 Methods of inactivation or attenuation
- 2770/32262 by genetic engineering
- 2770/32263 by chemical treatment
- 2770/32264 by serial passage
- 2770/32271 Demonstrated in vivo effect

2770/32288	For redistribution	2770/32444	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32311	. . .	Enterovirus	2770/32445	Special targeting system for viral vectors
2770/32321	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/32451	Methods of production or purification of viral material
2770/32322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2770/32452	relating to complementing cells and packaging systems for producing virus or viral particles
2770/32323	Virus like particles [VLP]	2770/32461	Methods of inactivation or attenuation
2770/32331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2770/32462	by genetic engineering
2770/32332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2770/32463	by chemical treatment
2770/32333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2770/32464	by serial passage
2770/32334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2770/32471	Demonstrated <u>in vivo</u> effect
2770/32341	Use of virus, viral particle or viral elements as a vector	2770/32488	For redistribution
2770/32342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2770/32511	. . .	Parechovirus, e.g. human parechovirus
2770/32343	viral genome or elements thereof as genetic vector	2770/32521	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/32522	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32345	Special targeting system for viral vectors	2770/32523	Virus like particles [VLP]
2770/32351	Methods of production or purification of viral material	2770/32531	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32352	relating to complementing cells and packaging systems for producing virus or viral particles	2770/32532	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32361	Methods of inactivation or attenuation	2770/32533	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32362	by genetic engineering	2770/32534	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32363	by chemical treatment	2770/32541	Use of virus, viral particle or viral elements as a vector
2770/32364	by serial passage	2770/32542	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32371	Demonstrated <u>in vivo</u> effect	2770/32543	viral genome or elements thereof as genetic vector
2770/32388	For redistribution	2770/32544	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32411	. . .	Hepatovirus, i.e. hepatitis A virus	2770/32545	Special targeting system for viral vectors
2770/32421	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/32551	Methods of production or purification of viral material
2770/32422	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2770/32552	relating to complementing cells and packaging systems for producing virus or viral particles
2770/32423	Virus like particles [VLP]	2770/32561	Methods of inactivation or attenuation
2770/32431	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2770/32562	by genetic engineering
2770/32432	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2770/32563	by chemical treatment
2770/32433	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2770/32564	by serial passage
2770/32434	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2770/32571	Demonstrated <u>in vivo</u> effect
2770/32441	Use of virus, viral particle or viral elements as a vector	2770/32588	For redistribution
2770/32442	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2770/32611	. . .	Poliovirus
2770/32443	viral genome or elements thereof as genetic vector	2770/32621	Viruses as such, e.g. new isolates, mutants or their genomic sequences
			2770/32622	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
			2770/32623	Virus like particles [VLP]
			2770/32631	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
			2770/32632	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/32633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32641 Use of virus, viral particle or viral elements as a vector
- 2770/32642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32643 viral genome or elements thereof as genetic vector
- 2770/32644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32645 Special targeting system for viral vectors
- 2770/32651 Methods of production or purification of viral material
- 2770/32652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32661 Methods of inactivation or attenuation
- 2770/32662 by genetic engineering
- 2770/32663 by chemical treatment
- 2770/32664 by serial passage
- 2770/32671 Demonstrated in vivo effect
- 2770/32688 For redistribution
- 2770/32711 . . . Rhinovirus
- 2770/32721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32723 Virus like particles [VLP]
- 2770/32731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32741 Use of virus, viral particle or viral elements as a vector
- 2770/32742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32743 viral genome or elements thereof as genetic vector
- 2770/32744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32745 Special targeting system for viral vectors
- 2770/32751 Methods of production or purification of viral material
- 2770/32752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32761 Methods of inactivation or attenuation
- 2770/32762 by genetic engineering
- 2770/32763 by chemical treatment
- 2770/32764 by serial passage
- 2770/32771 Demonstrated in vivo effect
- 2770/32788 For redistribution
- 2770/34011 . . Potyviridae
- 2770/34021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/34022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/34023 . . . Virus like particles [VLP]
- 2770/34031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/34032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/34033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/34034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/34041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/34042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/34043 viral genome or elements thereof as genetic vector
- 2770/34044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/34045 Special targeting system for viral vectors
- 2770/34051 . . . Methods of production or purification of viral material
- 2770/34052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/34061 . . . Methods of inactivation or attenuation
- 2770/34062 by genetic engineering
- 2770/34063 by chemical treatment
- 2770/34064 by serial passage
- 2770/34071 . . . Demonstrated in vivo effect
- 2770/34088 . . . For redistribution
- 2770/36011 . . Togaviridae
- 2770/36021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36023 . . . Virus like particles [VLP]
- 2770/36031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/36042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36043 viral genome or elements thereof as genetic vector

- 2770/36044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36045 Special targeting system for viral vectors
- 2770/36051 Methods of production or purification of viral material
- 2770/36052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36061 Methods of inactivation or attenuation
- 2770/36062 by genetic engineering
- 2770/36063 by chemical treatment
- 2770/36064 by serial passage
- 2770/36071 Demonstrated in vivo effect
- 2770/36088 For redistribution
- 2770/36111 Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- 2770/36121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36123 Virus like particles [VLP]
- 2770/36131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36141 Use of virus, viral particle or viral elements as a vector
- 2770/36142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36143 viral genome or elements thereof as genetic vector
- 2770/36144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36145 Special targeting system for viral vectors
- 2770/36151 Methods of production or purification of viral material
- 2770/36152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36161 Methods of inactivation or attenuation
- 2770/36162 by genetic engineering
- 2770/36163 by chemical treatment
- 2770/36164 by serial passage
- 2770/36171 Demonstrated in vivo effect
- 2770/36188 For redistribution
- 2770/36211 Rubivirus, e.g. rubella virus
- 2770/36221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36223 Virus like particles [VLP]
- 2770/36231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36241 Use of virus, viral particle or viral elements as a vector
- 2770/36242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36243 viral genome or elements thereof as genetic vector
- 2770/36244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36245 Special targeting system for viral vectors
- 2770/36251 Methods of production or purification of viral material
- 2770/36252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36261 Methods of inactivation or attenuation
- 2770/36262 by genetic engineering
- 2770/36263 by chemical treatment
- 2770/36264 by serial passage
- 2770/36271 Demonstrated in vivo effect
- 2770/36288 For redistribution
- 2770/38011 Tombusviridae
- 2770/38021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/38022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/38023 Virus like particles [VLP]
- 2770/38031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/38032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/38033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/38034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/38041 Use of virus, viral particle or viral elements as a vector
- 2770/38042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/38043 viral genome or elements thereof as genetic vector
- 2770/38044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/38045 Special targeting system for viral vectors
- 2770/38051 Methods of production or purification of viral material
- 2770/38052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/38061 Methods of inactivation or attenuation
- 2770/38062 by genetic engineering
- 2770/38063 by chemical treatment

- 2770/38064 by serial passage
- 2770/38071 . . . Demonstrated in vivo effect
- 2770/38088 . . . For redistribution
- 2770/40011 . . Tymoviridae
- 2770/40021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/40022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/40023 . . . Virus like particles [VLP]
- 2770/40031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/40032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/40033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/40034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/40041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/40042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/40043 viral genome or elements thereof as genetic vector
- 2770/40044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/40045 Special targeting system for viral vectors
- 2770/40051 . . . Methods of production or purification of viral material
- 2770/40052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/40061 . . . Methods of inactivation or attenuation
- 2770/40062 by genetic engineering
- 2770/40063 by chemical treatment
- 2770/40064 by serial passage
- 2770/40071 . . . Demonstrated in vivo effect
- 2770/40088 . . . For redistribution
- 2780/00** **Naked RNA Viruses (not used)**
- 2780/00011 . Naked RNA Viruses
- 2780/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/00023 . . Virus like particles [VLP]
- 2780/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/00041 . . Use of virus, viral particle or viral elements as a vector
- 2780/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/00043 . . . viral genome or elements thereof as genetic vector
- 2780/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/00045 Special targeting system for viral vectors
- 2780/00051 . . . Methods of production or purification of viral material
- 2780/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/00061 . . . Methods of inactivation or attenuation
- 2780/00062 by genetic engineering
- 2780/00063 by chemical treatment
- 2780/00064 by serial passage
- 2780/00071 . . . Demonstrated in vivo effect
- 2780/00088 . . . For redistribution
- 2780/00043** viral genome or elements thereof as genetic vector
- 2780/00044** . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/00045** Special targeting system for viral vectors
- 2780/00051** . . . Methods of production or purification of viral material
- 2780/00052** relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/00061** . . . Methods of inactivation or attenuation
- 2780/00062** by genetic engineering
- 2780/00063** by chemical treatment
- 2780/00064** by serial passage
- 2780/00071** . . . Demonstrated in vivo effect
- 2780/00088** . . . For redistribution
- 2780/10011** Narnaviridae
- 2780/10021** Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/10022** New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/10023** Virus like particles [VLP]
- 2780/10031** Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/10032** Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/10033** Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/10034** Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/10041** Use of virus, viral particle or viral elements as a vector
- 2780/10042** virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/10043** viral genome or elements thereof as genetic vector
- 2780/10044** Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/10045** Special targeting system for viral vectors
- 2780/10051** Methods of production or purification of viral material
- 2780/10052** relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/10061** Methods of inactivation or attenuation
- 2780/10062** by genetic engineering
- 2780/10063** by chemical treatment
- 2780/10064** by serial passage
- 2780/10071** Demonstrated in vivo effect
- 2780/10088** For redistribution
- 2790/00** **Viroids and subviral agents (not used)**
- 2790/00011 . Viroids and subviral agents
- 2790/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/00023 . . Virus like particles [VLP]

- 2790/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/00041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/00043 viral genome or elements thereof as genetic vector
- 2790/00044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/00045 Special targeting system for viral vectors
- 2790/00051 . . . Methods of production or purification of viral material
- 2790/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/00061 . . . Methods of inactivation or attenuation
- 2790/00062 by genetic engineering
- 2790/00063 by chemical treatment
- 2790/00064 by serial passage
- 2790/00071 . . . Demonstrated in vivo effect
- 2790/00088 . . . For redistribution
- 2790/10011 . . . Prions
- 2790/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/10023 Virus like particles [VLP]
- 2790/10031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/10032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/10033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/10041 Use of virus, viral particle or viral elements as a vector
- 2790/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/10043 viral genome or elements thereof as genetic vector
- 2790/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/10045 Special targeting system for viral vectors
- 2790/10051 Methods of production or purification of viral material
- 2790/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/10061 Methods of inactivation or attenuation
- 2790/10062 by genetic engineering
- 2790/10063 by chemical treatment
- 2790/10064 by serial passage
- 2790/10071 Demonstrated in vivo effect
- 2790/10088 For redistribution
- 2790/12011 Satellite viruses
- 2790/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/12023 Virus like particles [VLP]
- 2790/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/12041 Use of virus, viral particle or viral elements as a vector
- 2790/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/12043 viral genome or elements thereof as genetic vector
- 2790/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/12045 Special targeting system for viral vectors
- 2790/12051 Methods of production or purification of viral material
- 2790/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/12061 Methods of inactivation or attenuation
- 2790/12062 by genetic engineering
- 2790/12063 by chemical treatment
- 2790/12064 by serial passage
- 2790/12071 Demonstrated in vivo effect
- 2790/12088 For redistribution
- 2790/14011 Viroids
- 2790/14021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/14022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/14023 Virus like particles [VLP]
- 2790/14031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/14032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/14033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/14034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/14041 Use of virus, viral particle or viral elements as a vector
- 2790/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule

2790/14043	viral genome or elements thereof as genetic vector	2792/10031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2790/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2792/10032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2790/14045	Special targeting system for viral vectors	2792/10033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2790/14051	Methods of production or purification of viral material	2792/10034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2790/14052	relating to complementing cells and packaging systems for producing virus or viral particles	2792/10041	Use of virus, viral particle or viral elements as a vector
2790/14061	Methods of inactivation or attenuation	2792/10042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2790/14062	by genetic engineering	2792/10043	viral genome or elements thereof as genetic vector
2790/14063	by chemical treatment	2792/10044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2790/14064	by serial passage	2792/10045	Special targeting system for viral vectors
2790/14071	Demonstrated <u>in vivo</u> effect	2792/10051	Methods of production or purification of viral material
2790/14088	For redistribution	2792/10052	relating to complementing cells and packaging systems for producing virus or viral particles
2792/00		Archaeobacteria viruses (not used)	2792/10061	Methods of inactivation or attenuation
2792/00011	Archaeobacteria viruses	2792/10062	by genetic engineering
2792/00021	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2792/10063	by chemical treatment
2792/00022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2792/10064	by serial passage
2792/00023	Virus like particles [VLP]	2792/10071	Demonstrated <u>in vivo</u> effect
2792/00031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2792/10088	For redistribution
2792/00032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2792/12011	Guttaviridae
2792/00033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2792/12021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2792/00034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2792/12022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2792/00041	Use of virus, viral particle or viral elements as a vector	2792/12023	Virus like particles [VLP]
2792/00042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2792/12031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2792/00043	viral genome or elements thereof as genetic vector	2792/12032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2792/00044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2792/12033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2792/00045	Special targeting system for viral vectors	2792/12034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2792/00051	Methods of production or purification of viral material	2792/12041	Use of virus, viral particle or viral elements as a vector
2792/00052	relating to complementing cells and packaging systems for producing virus or viral particles	2792/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2792/00061	Methods of inactivation or attenuation	2792/12043	viral genome or elements thereof as genetic vector
2792/00062	by genetic engineering	2792/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2792/00063	by chemical treatment	2792/12045	Special targeting system for viral vectors
2792/00064	by serial passage	2792/12051	Methods of production or purification of viral material
2792/00071	Demonstrated <u>in vivo</u> effect	2792/12052	relating to complementing cells and packaging systems for producing virus or viral particles
2792/00088	For redistribution	2792/12061	Methods of inactivation or attenuation
2792/10011	Fuselloviridae			
2792/10021	Viruses as such, e.g. new isolates, mutants or their genomic sequences			
2792/10022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2792/10023	Virus like particles [VLP]			

- 2792/12062 by genetic engineering
- 2792/12063 by chemical treatment
- 2792/12064 by serial passage
- 2792/12071 . . . Demonstrated in vivo effect
- 2792/12088 . . . For redistribution
- 2795/00 Bacteriophages (not used)**
- 2795/00011 . Bacteriophages
- 2795/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/00023 . . Virus like particles [VLP]
- 2795/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/00041 . . Use of virus, viral particle or viral elements as a vector
- 2795/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/00043 . . . viral genome or elements thereof as genetic vector
- 2795/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/00045 . . . Special targeting system for viral vectors
- 2795/00051 . . Methods of production or purification of viral material
- 2795/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/00061 . . Methods of inactivation or attenuation
- 2795/00062 . . . by genetic engineering
- 2795/00063 . . . by chemical treatment
- 2795/00064 . . . by serial passage
- 2795/00071 . . Demonstrated in vivo effect
- 2795/00088 . . For redistribution
- 2795/10011 . . dsDNA Bacteriophages
- 2795/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10023 . . . Virus like particles [VLP]
- 2795/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10043 viral genome or elements thereof as genetic vector
- 2795/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10045 Special targeting system for viral vectors
- 2795/10051 . . . Methods of production or purification of viral material
- 2795/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10061 . . . Methods of inactivation or attenuation
- 2795/10062 by genetic engineering
- 2795/10063 by chemical treatment
- 2795/10064 by serial passage
- 2795/10071 . . . Demonstrated in vivo effect
- 2795/10088 . . . For redistribution
- 2795/10111 . . . Myoviridae
- 2795/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10123 Virus like particles [VLP]
- 2795/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10141 Use of virus, viral particle or viral elements as a vector
- 2795/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10143 viral genome or elements thereof as genetic vector
- 2795/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10145 Special targeting system for viral vectors
- 2795/10151 Methods of production or purification of viral material
- 2795/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10161 Methods of inactivation or attenuation
- 2795/10162 by genetic engineering
- 2795/10163 by chemical treatment
- 2795/10164 by serial passage
- 2795/10171 Demonstrated in vivo effect
- 2795/10188 For redistribution
- 2795/10211 . . . Podoviridae
- 2795/10221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10223 Virus like particles [VLP]

- 2795/10231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10241 Use of virus, viral particle or viral elements as a vector
- 2795/10242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10243 viral genome or elements thereof as genetic vector
- 2795/10244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10245 Special targeting system for viral vectors
- 2795/10251 Methods of production or purification of viral material
- 2795/10252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10261 Methods of inactivation or attenuation
- 2795/10262 by genetic engineering
- 2795/10263 by chemical treatment
- 2795/10264 by serial passage
- 2795/10271 Demonstrated *in vivo* effect
- 2795/10288 For redistribution
- 2795/10311 . . . Siphoviridae
- 2795/10321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10323 Virus like particles [VLP]
- 2795/10331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10341 Use of virus, viral particle or viral elements as a vector
- 2795/10342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10343 viral genome or elements thereof as genetic vector
- 2795/10344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10345 Special targeting system for viral vectors
- 2795/10351 Methods of production or purification of viral material
- 2795/10352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10361 Methods of inactivation or attenuation
- 2795/10362 by genetic engineering
- 2795/10363 by chemical treatment
- 2795/10364 by serial passage
- 2795/10371 Demonstrated *in vivo* effect
- 2795/10388 For redistribution
- 2795/12011 . . dsRNA Bacteriophages
- 2795/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/12023 . . . Virus like particles [VLP]
- 2795/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/12043 viral genome or elements thereof as genetic vector
- 2795/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/12045 Special targeting system for viral vectors
- 2795/12051 . . . Methods of production or purification of viral material
- 2795/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/12061 . . . Methods of inactivation or attenuation
- 2795/12062 by genetic engineering
- 2795/12063 by chemical treatment
- 2795/12064 by serial passage
- 2795/12071 . . . Demonstrated *in vivo* effect
- 2795/12088 . . . For redistribution
- 2795/14011 . . ssDNA Bacteriophages
- 2795/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14023 . . . Virus like particles [VLP]
- 2795/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule

2795/14043	viral genome or elements thereof as genetic vector	2795/14232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2795/14233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/14045	Special targeting system for viral vectors	2795/14234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/14051	Methods of production or purification of viral material	2795/14241	Use of virus, viral particle or viral elements as a vector
2795/14052	relating to complementing cells and packaging systems for producing virus or viral particles	2795/14242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/14061	Methods of inactivation or attenuation	2795/14243	viral genome or elements thereof as genetic vector
2795/14062	by genetic engineering	2795/14244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/14063	by chemical treatment	2795/14245	Special targeting system for viral vectors
2795/14064	by serial passage	2795/14251	Methods of production or purification of viral material
2795/14071	Demonstrated <u>in vivo</u> effect	2795/14252	relating to complementing cells and packaging systems for producing virus or viral particles
2795/14088	For redistribution	2795/14261	Methods of inactivation or attenuation
2795/14111	Inoviridae	2795/14262	by genetic engineering
2795/14121	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2795/14263	by chemical treatment
2795/14122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2795/14264	by serial passage
2795/14123	Virus like particles [VLP]	2795/14271	Demonstrated <u>in vivo</u> effect
2795/14131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2795/14288	For redistribution
2795/14132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2795/16011	ssRNA Bacteriophages negative-sense
2795/14133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2795/16021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/14134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2795/16022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/14141	Use of virus, viral particle or viral elements as a vector	2795/16023	Virus like particles [VLP]
2795/14142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2795/16031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/14143	viral genome or elements thereof as genetic vector	2795/16032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/14144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2795/16033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/14145	Special targeting system for viral vectors	2795/16034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/14151	Methods of production or purification of viral material	2795/16041	Use of virus, viral particle or viral elements as a vector
2795/14152	relating to complementing cells and packaging systems for producing virus or viral particles	2795/16042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/14161	Methods of inactivation or attenuation	2795/16043	viral genome or elements thereof as genetic vector
2795/14162	by genetic engineering	2795/16044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/14163	by chemical treatment	2795/16045	Special targeting system for viral vectors
2795/14164	by serial passage	2795/16051	Methods of production or purification of viral material
2795/14171	Demonstrated <u>in vivo</u> effect	2795/16052	relating to complementing cells and packaging systems for producing virus or viral particles
2795/14188	For redistribution	2795/16061	Methods of inactivation or attenuation
2795/14211	Microviridae	2795/16062	by genetic engineering
2795/14221	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2795/16063	by chemical treatment
2795/14222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2795/14223	Virus like particles [VLP]			
2795/14231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			

- 2795/16064 by serial passage
- 2795/16071 . . . Demonstrated in vivo effect
- 2795/16088 . . . For redistribution
- 2795/18011 . . ssRNA Bacteriophages positive-sense
- 2795/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/18023 . . . Virus like particles [VLP]
- 2795/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/18043 viral genome or elements thereof as genetic vector
- 2795/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/18045 Special targeting system for viral vectors
- 2795/18051 . . . Methods of production or purification of viral material
- 2795/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/18061 . . . Methods of inactivation or attenuation
- 2795/18062 by genetic engineering
- 2795/18063 by chemical treatment
- 2795/18064 by serial passage
- 2795/18071 . . . Demonstrated in vivo effect
- 2795/18088 . . . For redistribution
- 2795/18111 . . . Leviviridae
- 2795/18121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/18122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/18123 Virus like particles [VLP]
- 2795/18131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/18132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/18133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/18134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/18141 Use of virus, viral particle or viral elements as a vector
- 2795/18142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/18143 viral genome or elements thereof as genetic vector
- 2795/18144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/18145 Special targeting system for viral vectors
- 2795/18151 Methods of production or purification of viral material
- 2795/18152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/18161 Methods of inactivation or attenuation
- 2795/18162 by genetic engineering
- 2795/18163 by chemical treatment
- 2795/18164 by serial passage
- 2795/18171 Demonstrated in vivo effect
- 2795/18188 For redistribution
- 2799/00** **Uses of viruses**
- WARNING**
- From March 15, 2012 codes in the range [C12N 2799/00](#) - [C12N 2799/06](#) are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in [C12N 2710/00](#)-[C12N 2795/00](#)
- 2799/02 . . as vector
- 2799/021 . . for the expression of a heterologous nucleic acid
- 2799/022 . . . where the vector is derived from an adenovirus
- 2799/023 . . . where the vector is derived from a poxvirus
- 2799/025 . . . where the vector is derived from a parvovirus
- 2799/026 . . . where the vector is derived from a baculovirus
- 2799/027 . . . where the vector is derived from a retrovirus
- 2799/028 . . . where the vector is derived from a herpesvirus
- 2799/04 . . in vivo
- 2799/06 . . in vitro
- 2800/00** **Nucleic acids vectors**
- 2800/10 . Plasmid DNA
- 2800/101 . . for bacteria
- 2800/102 . . for yeast
- 2800/103 . . for invertebrates
- 2800/105 . . . for insects
- 2800/106 . . for vertebrates
- 2800/107 . . . for mammalian
- 2800/108 . . episomal vectors
- 2800/20 . Pseudochromosomes, minichromosomes
- 2800/202 . . of bacteriophage origin
- 2800/204 . . of bacterial origin, e.g. BAC
- 2800/206 . . of yeast origin, e.g. YAC, 2u
- 2800/208 . . of mammalian origin, e.g. minichromosome
- 2800/22 . Vectors comprising a coding region that has been codon optimised for expression in a respective host
- 2800/24 . Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
- 2800/30 . Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- 2800/40 . Systems of functionally co-operating vectors
- 2800/50 . Vectors for producing vectors
- 2800/60 . Vectors containing traps for, e.g. exons, promoters
- 2800/70 . Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites

2800/80	• Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
2800/90	• Vectors containing a transposable element
2800/95	• Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
2810/00	Vectors comprising a targeting moiety
2810/10	• Vectors comprising a non-peptidic targeting moiety
2810/40	• Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
2810/405	• • Vectors comprising RGD peptide
2810/50	• Vectors comprising as targeting moiety peptide derived from defined protein
2810/55	• • from bacteria
2810/60	• • from viruses
2810/6009	• • • dsDNA viruses
2810/6018	• • • • Adenoviridae
2810/6027	• • • ssDNA viruses
2810/6036	• • • DNA rev transcr viruses
2810/6045	• • • RNA rev transcr viruses
2810/6054	• • • • Retroviridae
2810/6063	• • • ds RNA viruses
2810/6072	• • • negative strand RNA viruses
2810/6081	• • • • rhabdoviridae, e.g. VSV
2810/609	• • • positive strand RNA viruses
2810/65	• • from plants
2810/70	• • from fungi
2810/75	• • from invertebrates
2810/80	• • from vertebrates
2810/85	• • • mammalian
2810/851	• • • • from growth factors; from growth regulators
2810/852	• • • • from cytokines; from lymphokines; from interferons
2810/853	• • • • • from tumor necrosis factor, TNF
2810/854	• • • • from hormones
2810/855	• • • • from receptors; from cell surface antigens; from cell surface determinants
2810/856	• • • • • from integrins
2810/857	• • • • from blood coagulation or fibrinolysis factors
2810/858	• • • • from apolipoproteins
2810/859	• • • • from immunoglobulins
2810/90	• • • avian
2820/00	Vectors comprising a special origin of replication system
2820/002	• inducible or controllable
2820/005	• cell-cycle regulated
2820/007	• tissue or cell-specific
2820/10	• multiple origins of replication
2820/55	• from bacteria
2820/60	• from viruses
2820/65	• from plants
2820/70	• from fungi
2820/702	• • yeast
2820/704	• • • S. cerevisiae
2820/706	• • • S. pombe
2820/708	• • • C. albicans
2820/75	• from invertebrates
2820/80	• from vertebrates
2820/85	• • mammalian
2820/90	• • avian
2830/00	Vector systems having a special element relevant for transcription
2830/001	• controllable enhancer/promoter combination
2830/002	• • inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
2830/003	• • • tet inducible
2830/005	• • repressible enhancer/promoter combination, e.g. KRAB
2830/006	• • • tet repressible
2830/007	• cell cycle specific enhancer/promoter combination
2830/008	• cell type or tissue specific enhancer/promoter combination
2830/15	• chimeric enhancer/promoter combination
2830/20	• transcription of more than one cistron
2830/205	• • bidirectional
2830/30	• being an enhancer not forming part of the promoter region
2830/32	• being a silencer not forming part of the promoter region
2830/34	• being a transcription initiation element
2830/36	• being a transcription termination element
2830/38	• being a stuffer
2830/40	• being an insulator
2830/42	• being an intron or intervening sequence for splicing and/or stability of RNA
2830/46	• elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
2830/48	• regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
2830/50	• regulating RNA stability, not being an intron, e.g. poly A signal
2830/52	• encoding ribozyme for self-inactivation
2830/55	• from bacteria
2830/60	• from viruses
2830/65	• from plants
2830/70	• from fungi
2830/702	• • yeast
2830/704	• • • S. cerevisiae
2830/706	• • • S. pombe
2830/708	• • • C. albicans
2830/75	• from invertebrates
2830/80	• from vertebrates
2830/85	• • mammalian
2830/90	• • avian
2840/00	Vectors comprising a special translation-regulating system
2840/002	• controllable or inducible
2840/005	• cell cycle specific
2840/007	• cell or tissue specific
2840/10	• regulates levels of translation
2840/102	• • inhibiting translation
2840/105	• • enhancing translation
2840/107	• • inhibiting translational read-through
2840/20	• translation of more than one cistron
2840/203	• • having an IRES
2840/206	• • • having multiple IRES
2840/44	• being a specific part of the splice mechanism, e.g. donor, acceptor
2840/445	• • for trans-splicing, e.g. polypyrimidine tract, branch point splicing

- 2840/50 . utilisation of non-ATG initiation codon

NOTE

This groups covers artificial modification only,
i.e. naturally occurring use of non-ATG start
codon is not classified here

- 2840/55 . from bacteria
- 2840/60 . from viruses
- 2840/65 . from plants
- 2840/70 . from fungi
- 2840/702 . . yeast
- 2840/704 . . . S. cerevisiae
- 2840/706 . . . S. pombe
- 2840/708 . . . C. albicans
- 2840/75 . from invertebrates
- 2840/80 . from vertebrates
- 2840/85 . . mammalian
- 2840/90 . . avian

- 2999/00 Further aspects of viruses or vectors not covered
by the [C12N 2700/00](#) or [C12N 2800/00](#) series**

NOTES

1. This group is for classification of patent and non-patent literature documents.
2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.

- 2999/002 . Adverse teaching
- 2999/005 . Biological teaching, e.g. a link between protein and disease, new virus causing pandemic
- 2999/007 . Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals